AbbVie (ABBV) 10-Q 4 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Oct. 27, 2020
Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-35565
Entity Registrant Name	AbbVie Inc.
Entity Central Index Key	0001551152
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0375147
Entity Address, Address Line One	1 North Waukegan Road
Entity Address, City or Town	North Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60064-6400
City Area Code	847
Local Phone Number	932-7900
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,765,473,923
Common Stock [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV
Security Exchange Name	NYSE
Common Stock [Member] | CHICAGO STOCK EXCHANGE, INC [Member]
Entity Information
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV
Security Exchange Name	CHX
Sec 1.375 Senior Notes Due 2024 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information
Title of 12(b) Security	1.375% Senior Notes due 2024
Trading Symbol	ABBV24
Security Exchange Name	NYSE
Sec 0.750 Senior Notes Due 2027 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information
Title of 12(b) Security	0.750% Senior Notes due 2027
Trading Symbol	ABBV27
Security Exchange Name	NYSE
Sec 2.125 Senior Notes due 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information
Title of 12(b) Security	2.125% Senior Notes due 2028
Trading Symbol	ABBV28
Security Exchange Name	NYSE
Sec 1.250 Senior Notes due 2031 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information
Title of 12(b) Security	1.250% Senior Notes due 2031
Trading Symbol	ABBV31
Security Exchange Name	NYSE

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Net revenues	$ 12,902	$ 8,479	$ 31,946	$ 24,562
Cost of products sold	5,050	1,920	10,703	5,433
Selling, general and administrative	2,846	1,657	8,068	4,991
Research and development	1,706	2,285	4,667	4,865
Acquired in-process research and development	45	0	898	246
Total operating costs and expenses	9,647	5,862	24,336	15,535
Operating earnings	3,255	2,617	7,610	9,027
Interest expense, net	620	420	1,662	1,054
Net foreign exchange loss	20	19	54	31
Other expense, net	115	177	989	2,590
Earnings before income tax expense	2,500	2,001	4,905	5,352
Income tax expense	187	117	321	271
Net earnings	2,313	1,884	4,584	5,081
Net earnings attributable to noncontrolling interest	5	0	4	0
Net earnings attributable to AbbVie Inc.	$ 2,308	$ 1,884	$ 4,580	$ 5,081
Per share data
Basic earnings per share (in dollars per share)	$ 1.30	$ 1.27	$ 2.78	$ 3.41
Diluted earnings per share (in dollars per share)	$ 1.29	$ 1.26	$ 2.77	$ 3.41
Weighted-average basic shares outstanding (in shares)	1,769	1,481	1,633	1,480
Weighted-average diluted shares outstanding (in shares)	1,774	1,483	1,637	1,483

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Net earnings	$ 2,313	$ 1,884	$ 4,584	$ 5,081
Foreign currency translation adjustments, net of tax expense (benefit) of $15 for the three months and $11 for the nine months ended September 30, 2020 and $(16) for the three months and $(10) for the nine months ended September 30, 2019	512	(256)	726	(288)
Net investment hedging activities, net of tax expense (benefit) of $(85) for the three months and $(125) for the nine months ended September 30, 2020 and $45 for the three months and $53 for the nine months ended September 30, 2019	(314)	156	(455)	184
Pension and post-employment benefits, net of tax expense (benefit) of $10 for the three months and $37 for the nine months ended September 30, 2020 and $7 for the three months and $19 for the nine months ended September 30, 2019	35	33	134	78
Marketable security activities, net of tax expense (benefit) of $— for the three months and $— for the nine months ended September 30, 2020 and $— for the three months and $— for the nine months ended September 30, 2019	0	(1)	0	10
Cash flow hedging activities, net of tax expense (benefit) of $(9) for the three months and $(13) for the nine months ended September 30, 2020 and $18 for the three months and $9 for the nine months ended September 30, 2019	(57)	31	(68)	(32)
Other comprehensive income (loss)	176	(37)	337	(48)
Comprehensive income	2,489	1,847	4,921	5,033
Comprehensive income attributable to noncontrolling interest	5	0	4	0
Comprehensive income attributable to AbbVie Inc.	$ 2,484	$ 1,847	$ 4,917	$ 5,033

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Foreign currency translation adjustments, tax expense (benefit)	$ 15	$ (16)	$ 11	$ (10)
Net investment hedging activities, tax expense (benefit)	(85)	45	(125)	53
Pension and post-employment benefits, tax expense (benefit)	10	7	37	19
Marketable security activities, tax expense (benefit)	0	0	0	0
Cash flow hedging activities, tax expense (benefit)	$ (9)	$ 18	$ (13)	$ 9

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Current assets
Cash and equivalents	$ 7,890	$ 39,924
Short-term investments	60	0
Accounts receivable, net	8,416	5,428
Inventories	3,474	1,813
Prepaid expenses and other	3,169	2,354
Total current assets	23,009	49,519
Investments	246	93
Property and equipment, net	4,986	2,962
Intangible assets, net	74,643	18,649
Goodwill	42,801	15,604
Other assets	3,936	2,288
Total assets	149,621	89,115
Current liabilities
Short-term borrowings	54	0
Current portion of long-term debt and finance lease obligations	4,723	3,753
Accounts payable and accrued liabilities	19,404	11,832
Total current liabilities	24,181	15,585
Long-term debt and finance lease obligations	82,282	62,975
Deferred income taxes	4,485	1,130
Other long-term liabilities	23,384	17,597
Commitments and contingencies
Stockholders’ equity (deficit)
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,789,544,701 shares issued as of September 30, 2020 and 1,781,582,608 as of December 31, 2019	18	18
Common stock held in treasury, at cost, 24,250,071 shares as of September 30, 2020 and 302,671,146 as of December 31, 2019	(1,972)	(24,504)
Additional paid-in capital	17,148	15,193
Retained earnings	3,335	4,717
Accumulated other comprehensive loss	(3,259)	(3,596)
Total stockholders' equity (deficit)	15,270	(8,172)
Noncontrolling interest	19	0
Total equity (deficit)	15,289	(8,172)
Total liabilities and equity	$ 149,621	$ 89,115

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	4,000,000,000	4,000,000,000
Common stock, issued (in shares)	1,789,544,701	1,781,582,608
Common stock held in treasury, at cost (in shares)	24,250,071	302,671,146

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common stock	Treasury stock	Additional paid-in capital	Retained earnings	Accumulated other comprehensive loss	Noncontrolling interest
Beginning balance at Dec. 31, 2018	$ (8,446)	$ 18	$ (24,108)	$ 14,756	$ 3,368	$ (2,480)	$ 0
Beginning balance (in shares) at Dec. 31, 2018		1,479
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	5,081	$ 0	0	0	5,081	0	0
Other comprehensive income (loss), net of tax	(48)	0	0	0	0	(48)	0
Dividends declared	(4,776)	0	0	0	(4,776)	0	0
Purchases of treasury stock	(425)	$ 0	(425)	0	0	0	0
Purchases of treasury stock (in shares)		(5)
Stock-based compensation plans and other	388	$ 0	32	356	0	0	0
Stock-based compensation plans and other (in shares)		5
Ending balance at Sep. 30, 2019	(8,226)	$ 18	(24,501)	15,112	3,673	(2,528)	0
Ending balance (in shares) at Sep. 30, 2019		1,479
Beginning balance at Jun. 30, 2019	(8,566)	$ 18	(24,505)	15,028	3,384	(2,491)	0
Beginning balance (in shares) at Jun. 30, 2019		1,478
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	1,884	$ 0	0	0	1,884	0	0
Other comprehensive income (loss), net of tax	(37)	0	0	0	0	(37)	0
Dividends declared	(1,595)	0	0	0	(1,595)	0	0
Purchases of treasury stock	(3)	$ 0	(3)	0	0	0	0
Purchases of treasury stock (in shares)		0
Stock-based compensation plans and other	91	$ 0	7	84	0	0	0
Stock-based compensation plans and other (in shares)		1
Ending balance at Sep. 30, 2019	(8,226)	$ 18	(24,501)	15,112	3,673	(2,528)	0
Ending balance (in shares) at Sep. 30, 2019		1,479
Beginning balance at Dec. 31, 2019	(8,172)	$ 18	(24,504)	15,193	4,717	(3,596)	0
Beginning balance (in shares) at Dec. 31, 2019		1,479
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	4,580	$ 0	0	0	4,580	0	0
Other comprehensive income (loss), net of tax	337	0	0	0	0	337	0
Dividends declared	(5,962)	0	0	0	(5,962)	0	0
Common shares and equity awards issued for acquisition of Allergan plc	24,409	$ 0	23,166	1,243	0	0	0
Common shares issued to Allergan plc stockholders (in shares)		286
Purchases of treasury stock	(682)	$ 0	(682)	0	0	0	0
Purchases of treasury stock (in shares)		(7)
Stock-based compensation plans and other	760	$ 0	48	712	0	0	0
Stock-based compensation plans and other (in shares)		7
Change in noncontrolling interest	19	$ 0	0	0	0	0	19
Ending balance at Sep. 30, 2020	15,289	$ 18	(1,972)	17,148	3,335	(3,259)	19
Ending balance (in shares) at Sep. 30, 2020		1,765
Beginning balance at Jun. 30, 2020	14,732	$ 18	(1,958)	16,953	3,130	(3,435)	24
Beginning balance (in shares) at Jun. 30, 2020		1,764
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	2,308	$ 0	0	0	2,308	0	0
Other comprehensive income (loss), net of tax	176	0	0	0	0	176	0
Dividends declared	(2,103)	0	0	0	(2,103)	0	0
Purchases of treasury stock	(20)	$ 0	(20)	0	0	0	0
Purchases of treasury stock (in shares)		0
Stock-based compensation plans and other	201	$ 0	6	195	0	0	0
Stock-based compensation plans and other (in shares)		1
Change in noncontrolling interest	(5)	$ 0	0	0	0	0	(5)
Ending balance at Sep. 30, 2020	$ 15,289	$ 18	$ (1,972)	$ 17,148	$ 3,335	$ (3,259)	$ 19
Ending balance (in shares) at Sep. 30, 2020		1,765

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Statement of Cash Flows [Abstract]
Net earnings	$ 4,584	$ 5,081
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	439	346
Amortization of intangible assets	3,967	1,162
Deferred income taxes	(498)	(77)
Change in fair value of contingent consideration liabilities	1,078	2,653
Stock-based compensation	617	351
Upfront costs and milestones related to collaborations	1,028	341
Intangible asset impairment	0	1,030
Other, net	491	92
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(574)	(207)
Inventories	(193)	(401)
Prepaid expenses and other assets	190	(89)
Accounts payable and other liabilities	1,903	494
Income tax assets and liabilities, net	(298)	(727)
Cash flows from operating activities	12,734	10,049
Cash flows from investing activities
Acquisition of businesses, net of cash acquired	(38,138)	0
Other acquisitions and investments	(1,072)	(476)
Acquisitions of property and equipment	(519)	(389)
Purchases of investment securities	(47)	(579)
Sales and maturities of investment securities	1,464	2,655
Other, net	1,382	0
Cash flows from investing activities	(36,930)	1,211
Cash flows from financing activities
Net change in commercial paper borrowings	0	(699)
Repayments of other short-term borrowings	0	(3,000)
Proceeds from issuance of long-term debt	3,000	1,534
Repayments of long-term debt and finance lease obligations	(4,414)	(5)
Repayments of long-term debt and finance lease obligations	(20)	(248)
Dividends paid	(5,615)	(4,771)
Purchases of treasury stock	(682)	(627)
Proceeds from the exercise of stock options	109	6
Payments of contingent consideration liabilities	(212)	(120)
Other, net	28	36
Cash flows from financing activities	(7,806)	(7,894)
Effect of exchange rate changes on cash and equivalents	(32)	(7)
Net change in cash and equivalents	(32,034)	3,359
Cash and equivalents, beginning of period	39,924	7,289
Cash and equivalents, end of period	7,890	10,648
Supplemental schedule of non-cash investing and financing activities
Issuance of common shares associated with acquisitions of businesses	$ 23,979	$ 0

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Basis of Historical Presentation The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company’s audited consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2019 . It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company’s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. Certain reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation. On May 8, 2020, AbbVie completed its previously announced acquisition of Allergan plc (Allergan). Refer to Note 4 for additional information regarding this acquisition. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements ASU No. 2016-13 In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments - Credit Losses (Topic 326) . The standard changes how credit losses are measured for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. AbbVie adopted the standard in the first quarter of 2020. The adoption did not have a material impact on the company's consolidated financial statements. Upon adoption of the standard, accounts receivable are stated at amortized cost less allowance for credit losses. The allowance for credit losses reflects the best estimate of future losses over the contractual life of outstanding accounts receivable and is determined on the basis of historical experience, specific allowances for known troubled accounts, other currently available information including customer financial condition, and both current and forecasted economic conditions. There were no significant changes in credit loss risk factors that impacted the company's recorded allowance during the nine months ended September 30, 2020 . Recent Accounting Pronouncements Not Yet Adopted ASU No. 2019-12 In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) . The standard includes simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard will be effective for AbbVie starting with the first quarter of 2021. AbbVie is currently assessing the impact of adopting this guidance but does not expect a material impact on its consolidated financial statements.

Supplemental Financial Informat

Supplemental Financial Information	9 Months Ended
	Sep. 30, 2020
Supplemental Financial Information
Supplemental Financial Information	Supplemental Financial Information Interest Expense, Net Three months ended Nine months ended (in millions) 2020 2019 2020 2019 Interest expense $ 630 $ 480 $ 1,825 $ 1,225 Interest income (10 ) (60 ) (163 ) (171 ) Interest expense, net $ 620 $ 420 $ 1,662 $ 1,054 Inventories (in millions) September 30, 2020 December 31, 2019 Finished goods $ 1,444 $ 485 Work-in-process 1,295 942 Raw materials 735 386 Inventories $ 3,474 $ 1,813 Property and Equipment (in millions) September 30, 2020 December 31, 2019 Property and equipment, gross $ 10,391 $ 8,188 Accumulated depreciation (5,405 ) (5,226 ) Property and equipment, net $ 4,986 $ 2,962 Depreciation expense was $175 million for the three months and $439 million for the nine months ended September 30, 2020 and $114 million for the three months and $346 million for the nine months ended September 30, 2019 .

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive. The following table summarizes the impact of the two-class method: Three months ended Nine months ended (in millions, except per share data) 2020 2019 2020 2019 Basic EPS Net earnings attributable to AbbVie Inc. $ 2,308 $ 1,884 $ 4,580 $ 5,081 Earnings allocated to participating securities 17 10 44 27 Earnings available to common shareholders $ 2,291 $ 1,874 $ 4,536 $ 5,054 Weighted-average basic shares outstanding 1,769 1,481 1,633 1,480 Basic earnings per share attributable to AbbVie Inc. $ 1.30 $ 1.27 $ 2.78 $ 3.41 Diluted EPS Net earnings attributable to AbbVie Inc. $ 2,308 $ 1,884 $ 4,580 $ 5,081 Earnings allocated to participating securities 17 10 44 27 Earnings available to common shareholders $ 2,291 $ 1,874 $ 4,536 $ 5,054 Weighted-average shares of common stock outstanding 1,769 1,481 1,633 1,480 Effect of dilutive securities 5 2 4 3 Weighted-average diluted shares outstanding 1,774 1,483 1,637 1,483 Diluted earnings per share attributable to AbbVie Inc. $ 1.29 $ 1.26 $ 2.77 $ 3.41 Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

Licensing, Acquisitions, and Ot

Licensing, Acquisitions, and Other Arrangements	9 Months Ended
	Sep. 30, 2020
Licensing, Acquisitions, and Other Arrangements
Licensing, Acquisitions, and Other Arrangements	Licensing, Acquisitions and Other Arrangements Acquisition of Allergan On May 8, 2020, AbbVie completed its previously announced acquisition of all outstanding equity interests in Allergan in a cash and stock transaction. Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The combination creates a diverse entity with leadership positions across immunology, hematologic oncology, aesthetics, neuroscience, eye care and women's health . AbbVie's existing product portfolio and pipeline is enhanced with numerous Allergan assets and Allergan's product portfolio benefits from AbbVie's commercial strength, expertise and international infrastructure. Under the terms of the acquisition, each ordinary share of Allergan common stock was converted into the right to receive (i) $120.30 in cash and (ii) 0.8660 of a share of AbbVie common stock. Total consideration for the acquisition of Allergan is summarized as follows: (in millions) Cash consideration paid to Allergan shareholders (a) $ 39,675 Fair value of AbbVie common stock issued to Allergan shareholders (b) 23,979 Fair value of AbbVie equity awards issued to Allergan equity award holders (c) 430 Total consideration $ 64,084 (a) Represents cash consideration transferred of $120.30 per outstanding Allergan ordinary share based on 330 million Allergan ordinary shares outstanding at closing. (b) Represents the acquisition date fair value of 286 million shares of AbbVie common stock issued to Allergan shareholders based on the exchange ratio of 0.8660 AbbVie shares for each outstanding Allergan ordinary share at the May 8, 2020 closing price of $83.96 per share. (c) Represents the pre-acquisition service portion of the fair value of 11 million AbbVie stock options and 8 million RSUs issued to Allergan equity award holders. The acquisition of Allergan has been accounted for as a business combination using the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The valuation of assets acquired and liabilities assumed has not yet been finalized as of September 30, 2020 . As a result, AbbVie recorded preliminary estimates for the fair value of assets acquired and liabilities assumed as of the acquisition date. Finalization of the valuation during the measurement period could result in a change in the amounts recorded for the acquisition date fair value of intangible assets, goodwill, property and equipment, inventories and income taxes among other items. The completion of the valuation will occur no later than one year from the acquisition date. The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date: (in millions) Assets acquired and liabilities assumed Cash and equivalents $ 1,537 Short-term investments 1,421 Accounts receivable 2,423 Inventories 2,340 Prepaid expenses and other current assets 1,984 Investments 137 Property and equipment 1,912 Intangible assets Developed product rights 58,280 In-process research and development 1,040 Other noncurrent assets 1,452 Short-term borrowings (60 ) Current portion of long-term debt and finance lease obligations (1,899 ) Accounts payable and accrued liabilities (5,813 ) Long-term debt and finance lease obligations (18,937 ) Deferred income taxes (4,068 ) Other long-term liabilities (4,728 ) Total identifiable net assets 37,021 Goodwill 27,063 Total assets acquired and liabilities assumed $ 64,084 The fair value step-up adjustment to inventories of $1.2 billion is being amortized to cost of products sold when the inventory is sold to customers, which is expected to be within approximately one year from the acquisition date. Intangible assets relate to $58.3 billion of developed product rights and $1.0 billion of in-process research and development (IPR&D). The acquired definite-lived intangible assets are being amortized over a weighted-average estimated useful life of approximately 9 years using the estimated pattern of economic benefit. The estimated fair values of identifiable intangible assets were determined using the "income approach" which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the more significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product (including net revenues, cost of products sold, research and development (R&D) costs, selling and marketing costs and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, competitive trends impacting the asset and each cash flow stream, as well as other factors. The fair value of long-term debt was determined by quoted market prices as of the acquisition date and the total purchase price adjustment of $1.3 billion is being amortized as a reduction to interest expense, net over the lives of the related debt. Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recognized from the acquisition of Allergan represents the value of additional growth platforms and an expanded revenue base as well as anticipated operational synergies and cost savings from the creation of a single combined global organization. The goodwill is not deductible for tax purposes. Following the acquisition date, the operating results of Allergan have been included in the condensed consolidated financial statements. For the period from the acquisition date through September 30, 2020 , net revenues attributable to Allergan were $5.9 billion and operating losses attributable to Allergan were $1.5 billion , inclusive of $2.6 billion of intangible asset amortization and $964 million of inventory fair value step-up amortization. Acquisition-related expenses, which were comprised primarily of regulatory, financial advisory and legal fees, totaled $781 million for the nine months ended September 30, 2020 and $26 million for the three months and $50 million for the nine months ended September 30, 2019 and were included in selling, general and administrative (SG&A) expenses in the condensed consolidated statements of earnings . There were no acquisition-related expenses for the three months ended September 30, 2020 . Pro Forma Financial Information The following table presents the unaudited pro forma combined results of AbbVie and Allergan for the three and nine months ended September 30, 2020 and 2019 as if the acquisition of Allergan had occurred on January 1, 2019: Three months ended Nine months ended (in millions) 2020 2019 2020 2019 Net revenues $ 12,902 $ 12,428 $ 36,663 $ 36,085 Net earnings (loss) 2,829 977 6,142 (2,615 ) The unaudited pro forma condensed combined financial information was prepared using the acquisition method of accounting and was based on the historical financial information of AbbVie and Allergan. In order to reflect the occurrence of the acquisition on January 1, 2019 as required, the unaudited pro forma financial information includes adjustments to reflect incremental amortization expense to be incurred based on the current preliminary fair values of the identifiable intangible assets acquired; the incremental cost of products sold related to the fair value adjustments associated with acquisition date inventory; the additional interest expense associated with the issuance of debt to finance the acquisition; and the reclassification of acquisition-related costs incurred during the three and nine months ended September 30, 2020 to the nine months ended September 30, 2019 . The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations would have been had the acquisition been completed on January 1, 2019. In addition, the unaudited pro forma financial information is not a projection of future results of operations of the combined company nor does it reflect the expected realization of any synergies or cost savings associated with the acquisition. Other Licensing & Acquisitions Activity Cash outflows related to other acquisitions and investments totaled $1.1 billion for the nine months ended September 30, 2020 and $476 million for the nine months ended September 30, 2019 . AbbVie recorded acquired IPR&D charges of $45 million for the three months and $898 million for the nine months ended September 30, 2020 . AbbVie recorded no acquired IPR&D charges for the three months and $246 million for the nine months ended September 30, 2019 . Genmab A/S In June 2020, AbbVie and Genmab A/S (Genmab) entered into a collaboration agreement to jointly develop and commercialize three of Genmab's early-stage investigational bispecific antibody therapeutics and entered into a discovery research collaboration for future differentiated antibody therapeutics for the treatment of cancer. Under the terms of the agreement, Genmab granted to AbbVie an exclusive license to its epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37 and DuoBody-CD3x5T4 programs. For epcoritamab, the companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Genmab will record net revenues in the U.S. and Japan, and the parties will share equally in pre-tax profits from these sales. Genmab will receive tiered royalties on remaining global sales. For the discovery research partnership, Genmab will conduct Phase 1 studies for these programs and AbbVie retains the right to opt-in to program development. AbbVie made an upfront payment of $750 million , which was recorded to IPR&D in the nine months ended September 30, 2020 . AbbVie could make additional payments of up to $3.2 billion upon the achievement of certain development, regulatory and commercial milestones for all programs. I-Mab Biopharma In September 2020, AbbVie and I-Mab Biopharma (I-Mab) entered into a collaboration agreement for the development and commercialization of lemzoparlimab, an anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. Both companies will collaborate to design and conduct further global clinical trials to evaluate lemzoparlimab. The collaboration provides AbbVie an exclusive global license, excluding greater China, to develop and commercialize lemzoparlimab. The companies will share manufacturing responsibilities with AbbVie being the primary manufacturer for global supply. The agreement also allows for potential collaboration on future CD47-related therapeutic agents, subject to further licenses to explore each other's related programs in their respective territories. The terms of the arrangement include an initial upfront payment of $180 million to exclusively license lemzoparlimab along with a milestone payment of $20 million based on the Phase I results, for a total of $200 million , which is expected to be recorded to IPR&D in the fourth quarter of 2020 after regulatory approval of the transaction. In addition, I-Mab will be eligible to receive up to $1.7 billion upon the achievement of certain clinical development, regulatory and commercial milestones, and AbbVie will pay tiered royalties from low-to-mid teen percentages on global net revenues outside of greater China. Luminera In October 2020, AbbVie entered into an agreement with Luminera, a privately held aesthetics company based in Israel, to acquire Luminera's full dermal filler portfolio and R&D pipeline including HArmonyCa, a dermal filler intended for facial soft tissue augmentation, for an aggregate purchase price comprised of an upfront payment of approximately $121 million plus contingent consideration up to $90 million upon achievement of certain commercial milestones. HArmonyCa is currently commercially available in Israel and Brazil and AbbVie will continue to develop this product for its international and U.S. markets.

Collaborations

Collaborations	9 Months Ended
	Sep. 30, 2020
Collaborative Arrangements [Abstract]
Collaborations	Collaborations The company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting the periods ended September 30, 2020 and 2019 . Collaboration with Janssen Biotech, Inc. In December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton's tyrosine kinase (BTK) and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States. The collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs. In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of Imbruvica are included in AbbVie's net revenues . Janssen's share of profits is included in AbbVie's cost of products sold . Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share. Outside the United States, Janssen is responsible for and has exclusive rights to commercialize Imbruvica. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues . Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share. The following table shows the profit and cost sharing relationship between Janssen and AbbVie: Three months ended Nine months ended (in millions) 2020 2019 2020 2019 United States - Janssen's share of profits (included in cost of products sold) $ 524 $ 489 $ 1,467 $ 1,297 International - AbbVie's share of profits (included in net revenues) 251 215 750 621 Global - AbbVie's share of other costs (included in respective line items) 74 81 211 230 AbbVie’s receivable from Janssen, included in accounts receivable, net, was $276 million at September 30, 2020 and $235 million at December 31, 2019 . AbbVie’s payable to Janssen, included in accounts payable and accrued liabilities, was $468 million at September 30, 2020 and $455 million at December 31, 2019 . Collaboration with Genentech, Inc. AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States. AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie's net revenues. Genentech's share of United States profits is included in AbbVie's cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of SG&A expenses and global development costs as part of R&D expenses, net of Genentech’s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie’s cost of products sold. The following table shows the profit and cost sharing relationship between Genentech and AbbVie: Three months ended Nine months ended (in millions) 2020 2019 2020 2019 Genentech's share of profits, including royalties (included in cost of products sold) $ 139 $ 89 $ 390 $ 220 AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) 9 9 34 27 AbbVie's share of development costs (included in R&D) 27 32 88 94

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill: (in millions) Balance as of December 31, 2019 $ 15,604 Additions (a) 27,063 Foreign currency translation adjustments 134 Balance as of September 30, 2020 $ 42,801 (a) Goodwill additions related to the acquisition of Allergan in the second quarter of 2020 (see Note 4 ). The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of September 30, 2020 , there were no accumulated goodwill impairment losses. Intangible Assets, Net The following table summarizes intangible assets: September 30, 2020 December 31, 2019 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 78,451 $ (9,917 ) $ 68,534 $ 19,547 $ (6,405 ) $ 13,142 License agreements 7,828 (2,759 ) 5,069 7,798 (2,291 ) 5,507 Total definite-lived intangible assets $ 86,279 $ (12,676 ) $ 73,603 $ 27,345 $ (8,696 ) $ 18,649 Indefinite-lived research and development 1,040 — 1,040 — — — Total intangible assets, net $ 87,319 $ (12,676 ) $ 74,643 $ 27,345 $ (8,696 ) $ 18,649 Definite-Lived Intangible Assets The increase in definite-lived intangible assets during 2020 was primarily due to the acquisition of Allergan in the second quarter of 2020. The intangible assets will be amortized using the estimated pattern of economic benefit. Refer to Note 4 for additional information regarding this acquisition. Amortization expense was $2.1 billion for the three months and $4.0 billion for the nine months ended September 30, 2020 and $389 million for the three months and $1.2 billion for the nine months ended September 30, 2019 . Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings . No definite-lived intangible asset impairment charges were recorded for the nine months ended September 30, 2020 and 2019 . Indefinite-Lived Intangible Assets Indefinite-lived intangible assets represents IPR&D associated with products that have not yet received regulatory approval. The increase in indefinite-lived research and development assets during 2020 was due to the acquisition of Allergan in the second quarter of 2020. Refer to Note 4 for additional information regarding this acquisition. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist. No indefinite-lived intangible asset impairment charges were recorded for the nine months ended September 30, 2020 . In the third quarter of 2019, following the announcement of the decision to terminate the rovalpituzumab tesirine (Rova-T) R&D program, the company recorded an impairment charge of $1.0 billion which represented the remaining value of the IPR&D acquired as part of the 2016 Stemcentrx acquisition.

Integration and Restructuring P

Integration and Restructuring Plans	9 Months Ended
	Sep. 30, 2020
Restructuring and Related Activities [Abstract]
Integration and Restructuring Plans	Integration and Restructuring Plans Allergan Integration Plan Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization. The integration plan is expected to realize more than $2 billion of expected annual cost synergies over a three-year period, with approximately 50% realized in R&D, 40% in SG&A and 10% in cost of products sold. To achieve these integration objectives, AbbVie expects to incur approximately $2 billion of charges through 2022. These costs will consist of severance and employee benefit costs (cash severance, non-cash severance, including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses. The following table summarizes the charges associated with the Allergan acquisition integration plan: Three months ended Nine months ended 2020 2020 (in millions) Severance and employee benefits Other integration Severance and employee benefits Other integration Cost of products sold $ 10 $ 12 $ 43 $ 13 Research and development 40 91 172 135 Selling, general and administrative 29 57 347 155 Total charges $ 79 $ 160 $ 562 $ 303 The following table summarizes the cash activity in the recorded liability associated with the integration plan: Nine months ended 2020 (in millions) Severance and employee benefits Other integration Charges $ 467 $ 303 Payments and other adjustments (178 ) (270 ) Accrued balance as of September 30, 2020 $ 289 $ 33 Other Restructuring AbbVie recorded restructuring charges of $11 million for the three months and $42 million for the nine months ended September 30, 2020 and $22 million for the three months and $208 million for the nine months ended September 30, 2019 . The following table summarizes the cash activity in the restructuring reserve for the nine months ended September 30, 2020 : (in millions) Accrued balance as of December 31, 2019 $ 140 Restructuring charges 40 Payments and other adjustments (87 ) Accrued balance as of September 30, 2020 $ 93

Financial Instruments and Fair

Financial Instruments and Fair Value Measures	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measures	Financial Instruments and Fair Value Measures Risk Management Policy See Note 11 to the company's Annual Report on Form 10-K for the year ended December 31, 2019 for a summary of AbbVie's risk management policy and use of derivative instruments. Financial Instruments Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $1.6 billion at September 30, 2020 and $957 million at December 31, 2019 , are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than 18 months . Accumulated gains and losses as of September 30, 2020 are reclassified from accumulated other comprehensive income (loss) (AOCI) and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement. In the third quarter of 2019, the company entered into treasury rate lock agreements with notional amounts totaling $10.0 billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in November 2019 and the resulting net gain was recognized in other comprehensive income (loss) . This gain is reclassified to interest expense, net over the term of the related debt. In the fourth quarter of 2019, the company entered into interest rate swap contracts with notional amounts totaling $2.3 billion at September 30, 2020 and December 31, 2019 . The effect of the hedge contracts is to change a floating-rate interest obligation to a fixed rate for that portion of the floating-rate debt. The contracts were designated as cash flow hedges and are recorded at fair value. Realized and unrealized gains or losses are included in AOCI and are reclassified to interest expense, net over the lives of the floating-rate debt. The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the condensed consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $8.3 billion at September 30, 2020 and $7.1 billion at December 31, 2019 . The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had foreign currency forward exchange contracts with notional amounts totaling €971 million , £204 million and CHF62 million at September 30, 2020 and December 31, 2019 . The company also had an aggregate principal amount of senior Euro notes designated as net investment hedges of €7.3 billion at September 30, 2020 and €3.6 billion at December 31, 2019 . The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument. AbbVie is a party to interest rate swap contracts designated as fair value hedges with notional amounts totaling $4.8 billion at September 30, 2020 and $10.8 billion at December 31, 2019 . The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges. The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets : Fair value – Fair value – (in millions) Balance sheet caption September 30, 2020 December 31, 2019 Balance sheet caption September 30, 2020 December 31, 2019 Foreign currency forward exchange contracts Designated as cash flow hedges Prepaid expenses and other $ — $ 3 Accounts payable and accrued liabilities $ 32 $ 14 Designated as net investment hedges Prepaid expenses and other 14 — Accounts payable and accrued liabilities 3 24 Not designated as hedges Prepaid expenses and other 35 19 Accounts payable and accrued liabilities 35 18 Interest rate swap contracts Designated as cash flow hedges Prepaid expenses and other — — Accounts payable and accrued liabilities 7 — Designated as cash flow hedges Other assets — 3 Other long-term liabilities 33 — Designated as fair value hedges Prepaid expenses and other 14 — Accounts payable and accrued liabilities — 2 Designated as fair value hedges Other assets 157 28 Other long-term liabilities — 74 Total derivatives $ 220 $ 53 $ 110 $ 132 While certain derivatives are subject to netting arrangements with the company’s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets . The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss) : Three months ended Nine months ended (in millions) 2020 2019 2020 2019 Foreign currency forward exchange contracts Designated as cash flow hedges $ (52 ) $ 3 $ (5 ) $ 8 Designated as net investment hedges (56 ) 59 (32 ) 69 Interest rate swap contracts designated as cash flow hedges (1 ) — (53 ) — Treasury rate lock agreements designated as cash flow hedges — 88 — 88 Assuming market rates remain constant through contract maturities, the company expects to reclassify pre-tax losses of $22 million into cost of products sold for foreign currency cash flow hedges, pre-tax losses of $27 million into interest expense, net for interest rate swap cash flow hedges and pre-tax gains of $24 million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months. Related to AbbVie’s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive income (loss) pre-tax losses of $340 million for the three months and pre-tax losses of $532 million for the nine months ended September 30, 2020 and recognized pre-tax gains of $152 million for the three months and pre-tax gains of $187 million for the nine months ended September 30, 2019 . The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings , including the net gains (losses) reclassified out of AOCI into net earnings . See Note 10 for the amount of net gains (losses) reclassified out of AOCI. Three months ended Nine months ended (in millions) Statement of earnings caption 2020 2019 2020 2019 Foreign currency forward exchange contracts Designated as cash flow hedges Cost of products sold $ 15 $ 42 $ 15 $ 119 Designated as net investment hedges Interest expense, net 3 10 16 19 Not designated as hedges Net foreign exchange loss 31 (55 ) 36 (95 ) Treasury rate lock agreements designated as cash flow hedges Interest expense, net 6 — 18 — Interest rate swap contracts Designated as cash flow hedges Interest expense, net (8 ) — (10 ) — Designated as fair value hedges Interest expense, net 1 78 398 443 Debt designated as hedged item in fair value hedges Interest expense, net (1 ) (78 ) (398 ) (443 ) Fair Value Measures The fair value hierarchy consists of the following three levels: • Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access; • Level 2 – Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and • Level 3 – Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company’s management about the assumptions market participants would use in pricing the asset or liability. The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of September 30, 2020 : Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 7,890 $ 2,836 $ 5,054 $ — Money market funds and time deposits 11 — 11 — Debt securities 53 — 53 — Equity securities 146 138 8 — Interest rate swap contracts 171 — 171 — Foreign currency contracts 49 — 49 — Total assets $ 8,320 $ 2,974 $ 5,346 $ — Liabilities Interest rate swap contracts $ 40 $ — $ 40 $ — Foreign currency contracts 70 — 70 — Contingent consideration 8,327 — — 8,327 Total liabilities $ 8,437 $ — $ 110 $ 8,327 The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2019 : Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 39,924 $ 1,542 $ 38,382 $ — Debt securities 3 — 3 — Equity securities 24 24 — — Interest rate swap contracts 31 — 31 — Foreign currency contracts 22 — 22 — Total assets $ 40,004 $ 1,566 $ 38,438 $ — Liabilities Interest rate swap contracts $ 76 $ — $ 76 $ — Foreign currency contracts 56 — 56 — Contingent consideration 7,340 — — 7,340 Total liabilities $ 7,472 $ — $ 132 $ 7,340 Equity securities consist of investments for which the fair values were determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies. The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. The potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of certain of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. The fair value of the company's contingent consideration liabilities as of September 30, 2020 was calculated using the following significant unobservable inputs: Range Weighted average (a) Discount rate 0.2% - 2.6% 1.5 % Probability of payment for unachieved milestones 16% - 57% 54 % Probability of payment for royalties by indication (b) 16% - 100% 89 % Projected year of payments 2020 - 2034 2027 (a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities. (b) Excludes early stage indications with 0% estimated probability of payment and includes approved indications with 100% probability of payment. Excluding approved indications, the estimated probability of payment ranged from 16% to 56% at September 30, 2020 . There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs: Nine months ended (in millions) 2020 2019 Beginning balance $ 7,340 $ 4,483 Additions (a) 121 — Change in fair value recognized in net earnings 1,078 2,653 Payments (212 ) (179 ) Ending balance $ 8,327 $ 6,957 (a) Represents contingent consideration liabilities assumed in the Allergan acquisition. The change in fair value recognized in net earnings is recorded in other expense, net in the condensed consolidated statements of earnings . Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of September 30, 2020 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Liabilities Short-term borrowings $ 54 $ 54 $ — $ 54 $ — Current portion of long-term debt and finance lease obligations, excluding fair value hedges 4,709 4,732 4,279 453 — Long-term debt and finance lease obligations, excluding fair value hedges 81,972 90,201 88,589 1,612 — Total liabilities $ 86,735 $ 94,987 $ 92,868 $ 2,119 $ — The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2019 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Liabilities Current portion of long-term debt and finance lease obligations, excluding fair value hedges $ 3,755 $ 3,760 $ 3,753 $ 7 $ — Long-term debt and finance lease obligations, excluding fair value hedges 63,021 66,651 66,631 20 — Total liabilities $ 66,776 $ 70,411 $ 70,384 $ 27 $ — AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $96 million as of September 30, 2020 and $66 million as of December 31, 2019 . No significant cumulative upward or downward adjustments have been recorded for these investments as of September 30, 2020 . Concentrations of Risk Of total net accounts receivable, three U.S. wholesalers accounted for 67% as of September 30, 2020 and 68% as of December 31, 2019 , and substantially all of AbbVie’s net revenues in the United States were to these three wholesalers. Humira (adalimumab) is AbbVie’s single largest product and accounted for approximately 46% of AbbVie’s total net revenues for the nine months ended September 30, 2020 and 58% for the nine months ended September 30, 2019 . Debt and Credit Facilities Allergan-Related Financing In connection with the acquisition of Allergan, in May 2020, the company borrowed $3.0 billion under a $6.0 billion term loan credit agreement, of which $1.0 billion was outstanding under a floating rate three-year term loan tranche and $2.0 billion outstanding under a floating rate five-year term loan tranche as of September 30, 2020 . Subsequent to these borrowings, AbbVie terminated the unused commitments of the lenders under the term loan. In May 2020, AbbVie completed its previously announced offers to exchange any and all outstanding notes of certain series issued by Allergan for new notes to be issued by AbbVie and cash. Following the settlement of the exchange offers, AbbVie issued $14.0 billion and €3.1 billion of new notes in exchange for the Allergan notes tendered in the exchange offers. The aggregate principal amount of Allergan notes that remained outstanding following the settlement of the exchange offers was approximately $1.5 billion and €635 million . The exchange transaction was accounted for as a modification of the assumed debt instruments. In September 2020, the company repaid $650 million aggregate principal amount of 3.375% Allergan exchange notes at maturity. The following table summarizes acquired debt outstanding as of September 30, 2020 : (dollars in millions) September 30, 2020 Senior USD notes 4.875% Senior Notes due 2021 $ 450 5.000% Senior Notes due 2021 1,200 3.450% Senior Notes due 2022 2,878 3.250% Senior Notes due 2022 1,700 2.800% Senior Notes due 2023 350 3.850% Senior Notes due 2024 1,032 3.800% Senior Notes due 2025 3,021 4.550% Senior Notes due 2035 1,789 4.625% Senior Notes due 2042 457 4.850% Senior Notes due 2044 1,074 4.750% Senior Notes due 2045 881 Senior Euro notes Floating Rate Notes due 2020 (€700 principal) 821 0.500% Senior Notes due 2021 (€750 principal) 879 1.500% Senior Notes due 2023 (€500 principal) 586 1.250% Senior Notes due 2024 (€700 principal) 821 2.625% Senior Notes due 2028 (€500 principal) 586 2.125% Senior Notes due 2029 (€550 principal) 645 Unamortized purchase price adjustments of Allergan debt 1,256 Total acquired debt outstanding $ 20,426 Other Long-Term Debt In May 2020, the company repaid $3.8 billion aggregate principal amount of 2.5% senior notes at maturity. In September 2019, the company issued €1.4 billion aggregate principal amount of unsecured senior Euro notes, consisting of €750 million aggregate principal amount of 0.75% senior notes due 2027 and €650 million aggregate principal amount of 1.25% senior notes due 2031. Short-Term Borrowings There were no commercial paper borrowings outstanding as of September 30, 2020 and December 31, 2019 . The weighted-average interest rate on commercial paper borrowings was 1.8% for the nine months ended September 30, 2020 and 2.5% for the nine months ended September 30, 2019 . In March 2019, AbbVie repaid its $3.0 billion 364 -day term loan credit agreement that was scheduled to mature in June 2019 .

Post-Employment Benefits

Post-Employment Benefits	9 Months Ended
	Sep. 30, 2020
Postemployment Benefits [Abstract]
Post-Employment Benefits	Post-Employment Benefits The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans: Defined Other post- Three months ended Nine months ended Three months ended Nine months ended (in millions) 2020 2019 2020 2019 2020 2019 2020 2019 Service cost $ 93 $ 67 $ 277 $ 202 $ 10 $ 6 $ 31 $ 19 Interest cost 68 64 196 194 8 6 25 21 Expected return on plan assets (148 ) (118 ) (426 ) (356 ) — — — — Amortization of actuarial losses and prior service cost 57 27 171 82 7 1 17 1 Net periodic benefit cost $ 70 $ 40 $ 218 $ 122 $ 25 $ 13 $ 73 $ 41 In connection with the Allergan acquisition, AbbVie assumed certain post-employment benefit obligations which were recorded at fair value. Upon acquisition in the second quarter of 2020, the excess of projected benefit obligations over the plan assets was recognized as a liability totaling $156 million . The components of net periodic benefit cost other than service cost are included in other expense, net in the condensed consolidated statements of earnings .

Equity

Equity	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Equity	Equity Stock-Based Compensation Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and is summarized as follows: Three months ended Nine months ended (in millions) 2020 2019 2020 2019 Cost of products sold $ 11 $ 4 $ 37 $ 24 Research and development 54 31 200 136 Selling, general and administrative 97 40 380 191 Pre-tax compensation expense 162 75 617 351 Tax benefit 32 15 109 64 After-tax compensation expense $ 130 $ 60 $ 508 $ 287 Stock Options During the nine months ended September 30, 2020 , primarily in connection with the company's annual grant, AbbVie granted 2.0 million stock options with a weighted-average grant-date fair value of $12.14 . In connection with the Allergan acquisition, during the second quarter of 2020, AbbVie issued 11.2 million stock options to holders of Allergan options as a result of the conversion of such options. These options were fair-valued using a lattice valuation model. Refer to Note 4 for additional information regarding the Allergan acquisition. As of September 30, 2020 , $16 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years . RSUs and Performance Shares During the nine months ended September 30, 2020 , primarily in connection with the company's annual grant, AbbVie granted 5.5 million RSUs and performance shares with a weighted-average grant-date fair value of $93.50 . In connection with the Allergan acquisition, during the second quarter of 2020, AbbVie issued 8.2 million RSUs to holders of Allergan equity awards based on a conversion factor described in the transaction agreement. Refer to Note 4 for additional information regarding the Allergan acquisition. As of September 30, 2020 , $713 million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years . Cash Dividends The following table summarizes quarterly cash dividends declared during 2020 and 2019 : 2020 2019 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share 10/30/20 02/16/21 $ 1.30 11/01/19 02/14/20 $ 1.18 09/11/20 11/16/20 $ 1.18 09/06/19 11/15/19 $ 1.07 06/17/20 08/14/20 $ 1.18 06/20/19 08/15/19 $ 1.07 02/20/20 05/15/20 $ 1.18 02/21/19 05/15/19 $ 1.07 Stock Repurchase Program The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes. Under this authorization, AbbVie repurchased 6 million shares for $500 million during the nine months ended September 30, 2020 and 4 million shares for $300 million during the nine months ended September 30, 2019 . AbbVie's remaining stock repurchase authorization was approximately $3.5 billion as of September 30, 2020 . Accumulated Other Comprehensive Loss The following table summarizes the changes in each component of accumulated other comprehensive loss , net of tax, for the nine months ended September 30, 2020 : (in millions) Foreign currency Net investment hedging activities Pension and post-employment Cash flow hedging Total Balance as of December 31, 2019 $ (928 ) $ 9 $ (2,965 ) $ 288 $ (3,596 ) Other comprehensive income (loss) before reclassifications 726 (443 ) (14 ) (49 ) 220 Net losses (gains) reclassified from accumulated other comprehensive loss — (12 ) 148 (19 ) 117 Net current-period other comprehensive income (loss) 726 (455 ) 134 (68 ) 337 Balance as of September 30, 2020 $ (202 ) $ (446 ) $ (2,831 ) $ 220 $ (3,259 ) Other comprehensive income for the nine months ended September 30, 2020 included foreign currency translation adjustments totaling a gain of $726 million , which was principally due to the impact of the strengthening of the Euro on the translation of the company’s Euro-denominated assets. The following table summarizes the changes in each component of accumulated other comprehensive loss , net of tax, for the nine months ended September 30, 2019 : (in millions) Foreign currency Net investment hedging activities Pension and post- Marketable security activities Cash flow hedging Total Balance as of December 31, 2018 $ (830 ) $ (65 ) $ (1,722 ) $ (10 ) $ 147 $ (2,480 ) Other comprehensive income (loss) before reclassifications (288 ) 199 12 12 77 12 Net losses (gains) reclassified from accumulated other comprehensive loss — (15 ) 66 (2 ) (109 ) (60 ) Net current-period other comprehensive income (loss) (288 ) 184 78 10 (32 ) (48 ) Balance as of September 30, 2019 $ (1,118 ) $ 119 $ (1,644 ) $ — $ 115 $ (2,528 ) Other comprehensive loss for the nine months ended September 30, 2019 included foreign currency translation adjustments totaling a loss of $288 million , which was principally due to the impact of the weakening of the Euro on the translation of the company’s Euro-denominated assets. The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss : Three months ended Nine months ended (in millions) (brackets denote gains) 2020 2019 2020 2019 Net investment hedging activities Gains on derivative amount excluded from effectiveness testing (a) $ (3 ) $ (10 ) $ (16 ) $ (19 ) Tax expense 1 2 4 4 Total reclassifications, net of tax $ (2 ) $ (8 ) $ (12 ) $ (15 ) Pension and post-employment benefits Amortization of actuarial losses and other (b) $ 63 $ 28 $ 188 $ 83 Tax benefit (13 ) (5 ) (40 ) (17 ) Total reclassifications, net of tax $ 50 $ 23 $ 148 $ 66 Cash flow hedging activities Gains on foreign currency forward exchange contracts (c) $ (15 ) $ (42 ) $ (15 ) $ (119 ) Gains on treasury rate lock agreements (a) (6 ) — (18 ) — Losses on interest rate swap contracts (a) 8 — 10 — Tax expense 3 3 4 10 Total reclassifications, net of tax $ (10 ) $ (39 ) $ (19 ) $ (109 ) (a) Amounts are included in interest expense, net (see Note 8 ). (b) Amounts are included in the computation of net periodic benefit cost (see Note 9 ). (c) Amounts are included in cost of products sold (see Note 8 ).

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The effective tax rate was 7% for the three and nine months ended September 30, 2020 and 6% for the three months and 5% for the nine months ended September 30, 2019 . The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the benefit from foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions and business development activities. The increase in the effective tax rate for the three and nine months ended September 30, 2020 over the prior year was principally due to the unfavorable impact of non-deductible Allergan acquisition related costs, the impact of changes in contingent consideration liabilities, collaboration related costs and changes in the company's taxable earnings among jurisdictions. Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible that the company’s gross unrecognized tax benefits balance may change within the next 12 months by up to $138 million .

Legal Proceedings and Contingen

Legal Proceedings and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings and Contingencies	Legal Proceedings and Contingencies AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. The recorded accrual balance for litigation was approximately $70 million as of September 30, 2020 and $290 million as of December 31, 2019 . Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie’s consolidated financial position, results of operations or cash flows. Subject to certain exceptions specified in the separation agreement by and between Abbott Laboratories (Abbott) and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters. Antitrust Litigation Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits pending in federal court consist of four individual plaintiff lawsuits and two consolidated purported class actions: one brought by Niaspan direct purchasers and one brought by Niaspan end-payers. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as In re: Niaspan Antitrust Litigation , MDL No. 2460. In August 2019, the court certified a class of direct purchasers of Niaspan. In June 2020, the court denied the end-payers' motion to certify a class. In October 2016, the Orange County, California District Attorney’s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys’ fees. In September 2014, the Federal Trade Commission filed a lawsuit, FTC v. AbbVie Inc., et al. , against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that 2011 patent litigation with two generic companies regarding AndroGel was sham litigation and the settlements of that litigation violated federal antitrust law. In May 2015, the court dismissed the FTC’s settlement-related claim. In June 2018, following a bench trial, the court found for the FTC on its sham litigation claim and ordered a disgorgement remedy of $448 million , plus prejudgment interest. The court denied the FTC’s request for injunctive relief. In September 2020, the United States Court of Appeals for the Third Circuit reversed the district court’s finding of sham litigation with respect to one generic company and affirmed with respect to the other but held the FTC lacked authority to obtain a disgorgement remedy and vacated the district court’s award. The Third Circuit also affirmed the district court’s denial of the FTC’s injunction request and reinstated the FTC’s settlement-related claim for further proceedings in the district court. In August 2019, direct purchasers of AndroGel filed a lawsuit, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al. , against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that 2006 patent litigation settlements and related agreements by Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) with three generic companies violated federal antitrust law, and also making allegations similar to those in FTC v. AbbVie Inc. (above). In May 2020, Perrigo Company and related entities filed a lawsuit against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, making sham litigation allegations similar to those in FTC v. AbbVie Inc . (above). In July 2019, the New Mexico Attorney General filed a lawsuit, State of New Mexico ex rel. Balderas v. AbbVie Inc., et al. , in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico’s Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act. Between March and May 2019, 12 putative class action lawsuits were filed in the United States District Court for the Northern District of Illinois by indirect Humira purchasers, alleging that AbbVie’s settlements with biosimilar manufacturers and AbbVie’s Humira patent portfolio violated state and federal antitrust laws. The court consolidated these lawsuits as In re: Humira (Adalimumab) Antitrust Litigation . In June 2020, the court dismissed the consolidated litigation with prejudice. The plaintiffs have appealed the dismissal. Lawsuits are pending against Forest Laboratories, LLC and others generally alleging that 2009 and 2010 patent litigation settlements involving Namenda entered into between Forest and generic companies and other conduct by Forest involving Namenda, violated state antitrust, unfair and deceptive trade practices, and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys’ fees. The lawsuits, purported class actions filed by indirect purchasers of Namenda, are consolidated as In re: Namenda Indirect Purchaser Antitrust Litigation in the United States District Court for the Southern District of New York. Lawsuits are pending against Allergan Inc. generally alleging that Allergan’s petitioning to the U.S. Patent Office and Food and Drug Administration and other conduct by Allergan involving Restasis violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys’ fees. The lawsuits, certified as a class action filed on behalf of indirect purchasers of Restasis, are consolidated for pre-trial purposes in the United States District Court for the Eastern District of New York under the MDL Rules as In re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation , MDL No. 2819. The settlement of similar lawsuits brought on behalf of a class of direct purchasers of Restasis received final court approval in October 2020. Government Proceedings Lawsuits are pending against Allergan and several other manufacturers generally alleging that they improperly promoted and sold prescription opioid products. Approximately 3,050 matters are pending against Allergan. The federal court cases are consolidated for pre-trial purposes in the United States District Court for the Northern District of Ohio under the MDL rules as In re: National Prescription Opiate Litigation , MDL No. 2804. Approximately 279 of the claims are pending in various state courts. The plaintiffs in these cases, which include states, counties, cities, and Native American tribes, generally seek compensatory damages. Shareholder and Securities Litigation In June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc. , was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connec tion with its proposed t ransaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of three plaintiffs, one of which refiled its lawsuit in New York state court in June 2020 while the appeal of its dismissal in Illinois is pending. Plaintiffs seek compensatory and punitive damages. In October 2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al ., was filed in the United States District Court for the Northern District of Illinois) against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2017 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In February 2020, a shareholder derivative lawsuit, Elfers v. Gonzalez, et al. , was filed in the United States District Court for the District of Delaware alleging that certain AbbVie directors and officers breached their fiduciary duties regarding alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value and in connection with the announcements of results of AbbVie’s 2018 Dutch auction tender offer. Lawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as In re: Allergan plc Securities Litigation . The plaintiffs generally seek compensatory damages and attorneys’ fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2020, the court denied plaintiffs’ class certification motion because it found the lead plaintiff to be an inadequate representative of the proposed class but allowed 30 days for another putative class member to propose itself as a new lead plaintiff. Lawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan’s former Actavis generics unit and its alleged anticompetitive conduct with other generic drug companies. The lawsuits were filed by Allergan shareholders and consist of three purported class actions and one individual action that have been consolidated in the U.S. District Court for the District of New Jersey as In re: Allergan Generic Drug Pricing Securities Litigation . Another individual action in New Jersey state court was dismissed in September 2020. The plaintiffs seek monetary damages and attorneys’ fees. Product Liability and General Litigation Product liability cases were filed generally alleging that AbbVie and other manufacturers of testosterone replacement therapy products did not adequately warn about risks of certain injuries, primarily heart attacks, strokes and blood clots. Approximately 3,500 claims against AbbVie regarding AndroGel were consolidated for pre-trial purposes in the United States District Court for the Northern District of Illinois under the MDL Rules as In re: Testosterone Replacement Therapy Products Liability Litigation , MDL No. 2545. Approximately 175 claims against AbbVie are pending in various state courts. All but five of the pending filed cases have been, or are in the process of being, dismissed pursuant to a Master Settlement Agreement. Product liability cases are pending in which plaintiffs generally allege that AbbVie did not adequately warn about risk of certain injuries, primarily various birth defects, arising from use of Depakote. Approximately 120 cases are pending in the United States District Court for the Southern District of Illinois, and approximately 4 others are pending in various federal and state courts. Plaintiffs generally seek compensatory and punitive damages. Approximately ninety-five percent of these pending cases, plus other unfiled claims, are subject to confidential settlement agreements and are expected to be dismissed with prejudice. In 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al. , was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit. Intellectual Property Litigation Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib capsules (a drug Pharmacyclics sells under the trademark Imbruvica). In February 2018 and March 2020, cases were filed in the United States District Court for the District of Delaware against Sandoz Inc. and Lek Pharmaceuticals D.D. In each case, Pharmacyclics alleges the defendants' proposed generic ibrutinib product infringes certain Pharmacyclics patents and seeks declaratory and injunctive relief. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits. Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 and March 2020 against Alvogen Pine Brook LLC and Natco Pharma Ltd., and in April 2020 against Zydus Worldwide DMCC and Cadila Healthcare Limited. In each case, Pharmacyclics alleges defendants’ proposed generic ibrutinib tablet product infringes certain Pharmacyclics patents and seeks declaratory and injunctive relief. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits. Allergan USA, Inc., Allergan Sales, LLC, and Forest Laboratories Holdings Limited, wholly owned subsidiaries of AbbVie, are seeking to enforce patent rights relating to cariprazine (a drug sold under the trademark Vraylar). Litigation was filed in the United States District Court for the District of Delaware in December 2019 against Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE; Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.; and Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited. Allergan alleges defendants' proposed generic cariprazine products infringe certain patents and seeks declaratory and injunctive relief. Gedeon Richter Plc, Inc. which is in a global collaboration with Allergan concerning the development and marketing of Vraylar, is the co-plaintiff in this suit. In January 2019, Allergan, Inc. and Allergan plc (now Allergan Limited) and Medytox Inc. (collectively, "Complainants") filed a complaint with the United States International Trade Commission (ITC) against Daewoong Pharmaceuticals Co., Ltd., Daewoong Co., Ltd., and Evolus Inc. (collectively, "Respondents") requesting the ITC commence an investigation regarding the importation into the United States of Respondents' botulinum neurotoxin products, including Jeuveau, which Complainants assert were developed using Medytox's trade secrets. Complainants seek permanent exclusion and cease and desist orders covering Respondents' products, including Jeuveau. In July 2020, the administrative law judge issued an initial ruling in favor of Allergan and Medytox. In September 2020, the full commission decided to review the initial ruling. In August 2020, BTL Industries, Inc. (BTL) filed an ITC action against Allergan USA, Inc., Allergan Limited, Allergan, Inc., Zeltiq Aesthetics, Inc., Zeltiq Ireland Unlimited Company, and Zimmer Medizinsysteme GmbH, for patent infringement alleging that the CoolTone and CoolSculpting devices infringe its patents and seeking an exclusion order preventing importation of the devices and any components used to make or use the devices.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Segment Information	Segment Information AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods. The following table details AbbVie’s worldwide net revenues: Three months ended Nine months ended (in millions) 2020 2019 2020 2019 Immunology Humira United States $ 4,189 $ 3,887 $ 11,819 $ 10,895 International 951 1,049 2,861 3,357 Total $ 5,140 $ 4,936 $ 14,680 $ 14,252 Skyrizi United States $ 379 $ 76 $ 934 $ 118 International 56 15 131 21 Total $ 435 $ 91 $ 1,065 $ 139 Rinvoq United States $ 191 $ 14 $ 409 $ 14 International 24 — 41 — Total $ 215 $ 14 $ 450 $ 14 Hematologic Oncology Imbruvica United States $ 1,119 $ 1,042 $ 3,140 $ 2,757 Collaboration revenues 251 215 750 621 Total $ 1,370 $ 1,257 $ 3,890 $ 3,378 Venclexta United States $ 204 $ 142 $ 596 $ 364 International 148 79 376 177 Total $ 352 $ 221 $ 972 $ 541 Aesthetics Botox Cosmetic (a) United States $ 237 $ — $ 384 $ — International 156 — 235 — Total $ 393 $ — $ 619 $ — Juvederm Collection (a) United States $ 115 $ — $ 171 $ — International 159 — 216 — Total $ 274 $ — $ 387 $ — Other Aesthetics (a) United States $ 265 $ — $ 392 $ — International 35 — 50 — Total $ 300 $ — $ 442 $ — Neuroscience Botox Therapeutic (a) United States $ 429 $ — $ 683 $ — International 94 — 137 — Total $ 523 $ — $ 820 $ — Vraylar (a) United States $ 358 $ — $ 550 $ — Duodopa United States $ 25 $ 26 $ 75 $ 72 International 98 91 290 271 Total $ 123 $ 117 $ 365 $ 343 Ubrelvy (a) United States $ 38 $ — $ 60 $ — Other Neuroscience (a) United States $ 203 $ — $ 306 $ — International 4 — 6 — Three months ended Nine months ended (in millions) 2020 2019 2020 2019 Total $ 207 $ — $ 312 $ — Eye Care Lumigan/Ganfort (a) United States $ 62 $ — $ 97 $ — International 87 — 128 — Total $ 149 $ — $ 225 $ — Alphagan/Combigan (a) United States $ 84 $ — $ 131 $ — International 39 — 61 — Total $ 123 $ — $ 192 $ — Restasis (a) United States $ 284 $ — $ 422 $ — International 15 — 21 — Total $ 299 $ — $ 443 $ — Other Eye Care (a) United States $ 119 $ — $ 173 $ — International 150 — 224 — Total $ 269 $ — $ 397 $ — Women's Health Lo Loestrin (a) United States $ 129 $ — $ 207 $ — International 5 — 7 — Total $ 134 $ — $ 214 $ — Orilissa/Oriahnn United States $ 24 $ 27 $ 84 $ 58 International 1 — 3 1 Total $ 25 $ 27 $ 87 $ 59 Other Women's Health (a) United States $ 74 $ — $ 108 $ — International 6 — 8 — Total $ 80 $ — $ 116 $ — Other Key Products Mavyret United States $ 185 $ 368 $ 565 $ 1,167 International 229 327 784 1,098 Total $ 414 $ 695 $ 1,349 $ 2,265 Creon United States $ 282 $ 265 $ 810 $ 749 Lupron United States $ 99 $ 187 $ 461 $ 546 International 34 43 110 122 Total $ 133 $ 230 $ 571 $ 668 Linzess/Constella (a) United States $ 240 $ — $ 370 $ — International 8 — 11 — Total $ 248 $ — $ 381 $ — Synthroid United States $ 189 $ 197 $ 577 $ 582 All other $ 829 $ 429 $ 1,972 $ 1,572 Total net revenues $ 12,902 $ 8,479 $ 31,946 $ 24,562 (a) Net revenues for the nine months ended September 30, 2020 include product revenues for Allergan products only from May 8, 2020, which was the acquisition closing date, through September 30, 2020 .

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements ASU No. 2016-13 In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments - Credit Losses (Topic 326) . The standard changes how credit losses are measured for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. AbbVie adopted the standard in the first quarter of 2020. The adoption did not have a material impact on the company's consolidated financial statements. Upon adoption of the standard, accounts receivable are stated at amortized cost less allowance for credit losses. The allowance for credit losses reflects the best estimate of future losses over the contractual life of outstanding accounts receivable and is determined on the basis of historical experience, specific allowances for known troubled accounts, other currently available information including customer financial condition, and both current and forecasted economic conditions. There were no significant changes in credit loss risk factors that impacted the company's recorded allowance during the nine months ended September 30, 2020 . Recent Accounting Pronouncements Not Yet Adopted ASU No. 2019-12 In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) . The standard includes simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard will be effective for AbbVie starting with the first quarter of 2021. AbbVie is currently assessing the impact of adopting this guidance but does not expect a material impact on its consolidated financial statements.

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	9 Months Ended
	Sep. 30, 2020
Supplemental Financial Information
Schedule of interest expense, net	Interest Expense, Net Three months ended Nine months ended (in millions) 2020 2019 2020 2019 Interest expense $ 630 $ 480 $ 1,825 $ 1,225 Interest income (10 ) (60 ) (163 ) (171 ) Interest expense, net $ 620 $ 420 $ 1,662 $ 1,054
Schedule of inventories	Inventories (in millions) September 30, 2020 December 31, 2019 Finished goods $ 1,444 $ 485 Work-in-process 1,295 942 Raw materials 735 386 Inventories $ 3,474 $ 1,813
Schedule of property and equipment	Property and Equipment (in millions) September 30, 2020 December 31, 2019 Property and equipment, gross $ 10,391 $ 8,188 Accumulated depreciation (5,405 ) (5,226 ) Property and equipment, net $ 4,986 $ 2,962

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule of basic and diluted earnings per share, impact of two-class method	The following table summarizes the impact of the two-class method: Three months ended Nine months ended (in millions, except per share data) 2020 2019 2020 2019 Basic EPS Net earnings attributable to AbbVie Inc. $ 2,308 $ 1,884 $ 4,580 $ 5,081 Earnings allocated to participating securities 17 10 44 27 Earnings available to common shareholders $ 2,291 $ 1,874 $ 4,536 $ 5,054 Weighted-average basic shares outstanding 1,769 1,481 1,633 1,480 Basic earnings per share attributable to AbbVie Inc. $ 1.30 $ 1.27 $ 2.78 $ 3.41 Diluted EPS Net earnings attributable to AbbVie Inc. $ 2,308 $ 1,884 $ 4,580 $ 5,081 Earnings allocated to participating securities 17 10 44 27 Earnings available to common shareholders $ 2,291 $ 1,874 $ 4,536 $ 5,054 Weighted-average shares of common stock outstanding 1,769 1,481 1,633 1,480 Effect of dilutive securities 5 2 4 3 Weighted-average diluted shares outstanding 1,774 1,483 1,637 1,483 Diluted earnings per share attributable to AbbVie Inc. $ 1.29 $ 1.26 $ 2.77 $ 3.41

Licensing, Acquisitions, and _2

Licensing, Acquisitions, and Other Arrangements (Tables)	9 Months Ended
	Sep. 30, 2020
Licensing, Acquisitions, and Other Arrangements
Schedule of consideration for the acquisition of Allergan	Total consideration for the acquisition of Allergan is summarized as follows: (in millions) Cash consideration paid to Allergan shareholders (a) $ 39,675 Fair value of AbbVie common stock issued to Allergan shareholders (b) 23,979 Fair value of AbbVie equity awards issued to Allergan equity award holders (c) 430 Total consideration $ 64,084 (a) Represents cash consideration transferred of $120.30 per outstanding Allergan ordinary share based on 330 million Allergan ordinary shares outstanding at closing. (b) Represents the acquisition date fair value of 286 million shares of AbbVie common stock issued to Allergan shareholders based on the exchange ratio of 0.8660 AbbVie shares for each outstanding Allergan ordinary share at the May 8, 2020 closing price of $83.96 per share. (c) Represents the pre-acquisition service portion of the fair value of 11 million AbbVie stock options and 8 million RSUs issued to Allergan equity award holders.
Schedule of fair value of assets acquired and liabilities assumed	The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date: (in millions) Assets acquired and liabilities assumed Cash and equivalents $ 1,537 Short-term investments 1,421 Accounts receivable 2,423 Inventories 2,340 Prepaid expenses and other current assets 1,984 Investments 137 Property and equipment 1,912 Intangible assets Developed product rights 58,280 In-process research and development 1,040 Other noncurrent assets 1,452 Short-term borrowings (60 ) Current portion of long-term debt and finance lease obligations (1,899 ) Accounts payable and accrued liabilities (5,813 ) Long-term debt and finance lease obligations (18,937 ) Deferred income taxes (4,068 ) Other long-term liabilities (4,728 ) Total identifiable net assets 37,021 Goodwill 27,063 Total assets acquired and liabilities assumed $ 64,084
Schedule of unaudited pro forma combined results	The following table presents the unaudited pro forma combined results of AbbVie and Allergan for the three and nine months ended September 30, 2020 and 2019 as if the acquisition of Allergan had occurred on January 1, 2019: Three months ended Nine months ended (in millions) 2020 2019 2020 2019 Net revenues $ 12,902 $ 12,428 $ 36,663 $ 36,085 Net earnings (loss) 2,829 977 6,142 (2,615 )

Collaborations (Tables)

Collaborations (Tables)	9 Months Ended
	Sep. 30, 2020
Janssen Biotech Inc.
Collaborative and license agreements
Schedule of profit and cost sharing relationship	The following table shows the profit and cost sharing relationship between Janssen and AbbVie: Three months ended Nine months ended (in millions) 2020 2019 2020 2019 United States - Janssen's share of profits (included in cost of products sold) $ 524 $ 489 $ 1,467 $ 1,297 International - AbbVie's share of profits (included in net revenues) 251 215 750 621 Global - AbbVie's share of other costs (included in respective line items) 74 81 211 230
Genentech, Inc.
Collaborative and license agreements
Schedule of profit and cost sharing relationship	The following table shows the profit and cost sharing relationship between Genentech and AbbVie: Three months ended Nine months ended (in millions) 2020 2019 2020 2019 Genentech's share of profits, including royalties (included in cost of products sold) $ 139 $ 89 $ 390 $ 220 AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) 9 9 34 27 AbbVie's share of development costs (included in R&D) 27 32 88 94

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of changes in the carrying amount of goodwill	The following table summarizes the changes in the carrying amount of goodwill: (in millions) Balance as of December 31, 2019 $ 15,604 Additions (a) 27,063 Foreign currency translation adjustments 134 Balance as of September 30, 2020 $ 42,801 (a) Goodwill additions related to the acquisition of Allergan in the second quarter of 2020 (see Note 4 ).
Summary of definite-lived intangible assets	The following table summarizes intangible assets: September 30, 2020 December 31, 2019 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 78,451 $ (9,917 ) $ 68,534 $ 19,547 $ (6,405 ) $ 13,142 License agreements 7,828 (2,759 ) 5,069 7,798 (2,291 ) 5,507 Total definite-lived intangible assets $ 86,279 $ (12,676 ) $ 73,603 $ 27,345 $ (8,696 ) $ 18,649 Indefinite-lived research and development 1,040 — 1,040 — — — Total intangible assets, net $ 87,319 $ (12,676 ) $ 74,643 $ 27,345 $ (8,696 ) $ 18,649
Summary of indefinite-lived intangible assets	The following table summarizes intangible assets: September 30, 2020 December 31, 2019 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 78,451 $ (9,917 ) $ 68,534 $ 19,547 $ (6,405 ) $ 13,142 License agreements 7,828 (2,759 ) 5,069 7,798 (2,291 ) 5,507 Total definite-lived intangible assets $ 86,279 $ (12,676 ) $ 73,603 $ 27,345 $ (8,696 ) $ 18,649 Indefinite-lived research and development 1,040 — 1,040 — — — Total intangible assets, net $ 87,319 $ (12,676 ) $ 74,643 $ 27,345 $ (8,696 ) $ 18,649

Integration and Restructuring_2

Integration and Restructuring Plans (Tables)	9 Months Ended
	Sep. 30, 2020
Allergan integration plan
Restructuring charges
Summary of charges associated with integration plan	The following table summarizes the charges associated with the Allergan acquisition integration plan: Three months ended Nine months ended 2020 2020 (in millions) Severance and employee benefits Other integration Severance and employee benefits Other integration Cost of products sold $ 10 $ 12 $ 43 $ 13 Research and development 40 91 172 135 Selling, general and administrative 29 57 347 155 Total charges $ 79 $ 160 $ 562 $ 303
Summary of cash activity in the restructuring reserve	The following table summarizes the cash activity in the recorded liability associated with the integration plan: Nine months ended 2020 (in millions) Severance and employee benefits Other integration Charges $ 467 $ 303 Payments and other adjustments (178 ) (270 ) Accrued balance as of September 30, 2020 $ 289 $ 33
Other restructuring
Restructuring charges
Summary of cash activity in the restructuring reserve	The following table summarizes the cash activity in the restructuring reserve for the nine months ended September 30, 2020 : (in millions) Accrued balance as of December 31, 2019 $ 140 Restructuring charges 40 Payments and other adjustments (87 ) Accrued balance as of September 30, 2020 $ 93

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measures (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Summary of amounts and location of derivatives on the condensed consolidated balance sheets	The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets : Fair value – Fair value – (in millions) Balance sheet caption September 30, 2020 December 31, 2019 Balance sheet caption September 30, 2020 December 31, 2019 Foreign currency forward exchange contracts Designated as cash flow hedges Prepaid expenses and other $ — $ 3 Accounts payable and accrued liabilities $ 32 $ 14 Designated as net investment hedges Prepaid expenses and other 14 — Accounts payable and accrued liabilities 3 24 Not designated as hedges Prepaid expenses and other 35 19 Accounts payable and accrued liabilities 35 18 Interest rate swap contracts Designated as cash flow hedges Prepaid expenses and other — — Accounts payable and accrued liabilities 7 — Designated as cash flow hedges Other assets — 3 Other long-term liabilities 33 — Designated as fair value hedges Prepaid expenses and other 14 — Accounts payable and accrued liabilities — 2 Designated as fair value hedges Other assets 157 28 Other long-term liabilities — 74 Total derivatives $ 220 $ 53 $ 110 $ 132
Schedule of pre-tax amounts of derivatives designated as cash flow hedges recognized in other comprehensive income (loss)	The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss) : Three months ended Nine months ended (in millions) 2020 2019 2020 2019 Foreign currency forward exchange contracts Designated as cash flow hedges $ (52 ) $ 3 $ (5 ) $ 8 Designated as net investment hedges (56 ) 59 (32 ) 69 Interest rate swap contracts designated as cash flow hedges (1 ) — (53 ) — Treasury rate lock agreements designated as cash flow hedges — 88 — 88
Schedule of pre-tax amounts of derivatives designated as net investment hedges recognized in other comprehensive income (loss)	The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss) : Three months ended Nine months ended (in millions) 2020 2019 2020 2019 Foreign currency forward exchange contracts Designated as cash flow hedges $ (52 ) $ 3 $ (5 ) $ 8 Designated as net investment hedges (56 ) 59 (32 ) 69 Interest rate swap contracts designated as cash flow hedges (1 ) — (53 ) — Treasury rate lock agreements designated as cash flow hedges — 88 — 88
Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings	The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings , including the net gains (losses) reclassified out of AOCI into net earnings . See Note 10 for the amount of net gains (losses) reclassified out of AOCI. Three months ended Nine months ended (in millions) Statement of earnings caption 2020 2019 2020 2019 Foreign currency forward exchange contracts Designated as cash flow hedges Cost of products sold $ 15 $ 42 $ 15 $ 119 Designated as net investment hedges Interest expense, net 3 10 16 19 Not designated as hedges Net foreign exchange loss 31 (55 ) 36 (95 ) Treasury rate lock agreements designated as cash flow hedges Interest expense, net 6 — 18 — Interest rate swap contracts Designated as cash flow hedges Interest expense, net (8 ) — (10 ) — Designated as fair value hedges Interest expense, net 1 78 398 443 Debt designated as hedged item in fair value hedges Interest expense, net (1 ) (78 ) (398 ) (443 )
Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis	The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of September 30, 2020 : Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 7,890 $ 2,836 $ 5,054 $ — Money market funds and time deposits 11 — 11 — Debt securities 53 — 53 — Equity securities 146 138 8 — Interest rate swap contracts 171 — 171 — Foreign currency contracts 49 — 49 — Total assets $ 8,320 $ 2,974 $ 5,346 $ — Liabilities Interest rate swap contracts $ 40 $ — $ 40 $ — Foreign currency contracts 70 — 70 — Contingent consideration 8,327 — — 8,327 Total liabilities $ 8,437 $ — $ 110 $ 8,327 The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2019 : Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 39,924 $ 1,542 $ 38,382 $ — Debt securities 3 — 3 — Equity securities 24 24 — — Interest rate swap contracts 31 — 31 — Foreign currency contracts 22 — 22 — Total assets $ 40,004 $ 1,566 $ 38,438 $ — Liabilities Interest rate swap contracts $ 76 $ — $ 76 $ — Foreign currency contracts 56 — 56 — Contingent consideration 7,340 — — 7,340 Total liabilities $ 7,472 $ — $ 132 $ 7,340
Summary of significant level 3 unobservable inputs	The fair value of the company's contingent consideration liabilities as of September 30, 2020 was calculated using the following significant unobservable inputs: Range Weighted average (a) Discount rate 0.2% - 2.6% 1.5 % Probability of payment for unachieved milestones 16% - 57% 54 % Probability of payment for royalties by indication (b) 16% - 100% 89 % Projected year of payments 2020 - 2034 2027 (a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities. (b) Excludes early stage indications with 0% estimated probability of payment and includes approved indications with 100% probability of payment. Excluding approved indications, the estimated probability of payment ranged from 16% to 56% at September 30, 2020 .
Schedule of changes in fair value of Level 3 inputs	The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs: Nine months ended (in millions) 2020 2019 Beginning balance $ 7,340 $ 4,483 Additions (a) 121 — Change in fair value recognized in net earnings 1,078 2,653 Payments (212 ) (179 ) Ending balance $ 8,327 $ 6,957 (a) Represents contingent consideration liabilities assumed in the Allergan acquisition.
Schedule of book values, approximate fair values and bases used to measure certain financial instruments	The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of September 30, 2020 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Liabilities Short-term borrowings $ 54 $ 54 $ — $ 54 $ — Current portion of long-term debt and finance lease obligations, excluding fair value hedges 4,709 4,732 4,279 453 — Long-term debt and finance lease obligations, excluding fair value hedges 81,972 90,201 88,589 1,612 — Total liabilities $ 86,735 $ 94,987 $ 92,868 $ 2,119 $ — The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2019 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Liabilities Current portion of long-term debt and finance lease obligations, excluding fair value hedges $ 3,755 $ 3,760 $ 3,753 $ 7 $ — Long-term debt and finance lease obligations, excluding fair value hedges 63,021 66,651 66,631 20 — Total liabilities $ 66,776 $ 70,411 $ 70,384 $ 27 $ —
Summary of acquired debt outstanding	The following table summarizes acquired debt outstanding as of September 30, 2020 : (dollars in millions) September 30, 2020 Senior USD notes 4.875% Senior Notes due 2021 $ 450 5.000% Senior Notes due 2021 1,200 3.450% Senior Notes due 2022 2,878 3.250% Senior Notes due 2022 1,700 2.800% Senior Notes due 2023 350 3.850% Senior Notes due 2024 1,032 3.800% Senior Notes due 2025 3,021 4.550% Senior Notes due 2035 1,789 4.625% Senior Notes due 2042 457 4.850% Senior Notes due 2044 1,074 4.750% Senior Notes due 2045 881 Senior Euro notes Floating Rate Notes due 2020 (€700 principal) 821 0.500% Senior Notes due 2021 (€750 principal) 879 1.500% Senior Notes due 2023 (€500 principal) 586 1.250% Senior Notes due 2024 (€700 principal) 821 2.625% Senior Notes due 2028 (€500 principal) 586 2.125% Senior Notes due 2029 (€550 principal) 645 Unamortized purchase price adjustments of Allergan debt 1,256 Total acquired debt outstanding $ 20,426

Post-Employment Benefits (Table

Post-Employment Benefits (Tables)	9 Months Ended
	Sep. 30, 2020
Postemployment Benefits [Abstract]
Summary of net periodic benefit costs relating to the company's defined benefit and other post-employment plans	The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans: Defined Other post- Three months ended Nine months ended Three months ended Nine months ended (in millions) 2020 2019 2020 2019 2020 2019 2020 2019 Service cost $ 93 $ 67 $ 277 $ 202 $ 10 $ 6 $ 31 $ 19 Interest cost 68 64 196 194 8 6 25 21 Expected return on plan assets (148 ) (118 ) (426 ) (356 ) — — — — Amortization of actuarial losses and prior service cost 57 27 171 82 7 1 17 1 Net periodic benefit cost $ 70 $ 40 $ 218 $ 122 $ 25 $ 13 $ 73 $ 41

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Summary of share-based compensation expense	Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and is summarized as follows: Three months ended Nine months ended (in millions) 2020 2019 2020 2019 Cost of products sold $ 11 $ 4 $ 37 $ 24 Research and development 54 31 200 136 Selling, general and administrative 97 40 380 191 Pre-tax compensation expense 162 75 617 351 Tax benefit 32 15 109 64 After-tax compensation expense $ 130 $ 60 $ 508 $ 287
Summary of quarterly cash dividends	The following table summarizes quarterly cash dividends declared during 2020 and 2019 : 2020 2019 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share 10/30/20 02/16/21 $ 1.30 11/01/19 02/14/20 $ 1.18 09/11/20 11/16/20 $ 1.18 09/06/19 11/15/19 $ 1.07 06/17/20 08/14/20 $ 1.18 06/20/19 08/15/19 $ 1.07 02/20/20 05/15/20 $ 1.18 02/21/19 05/15/19 $ 1.07
Summary of changes in balances of each component of accumulated other comprehensive loss	The following table summarizes the changes in each component of accumulated other comprehensive loss , net of tax, for the nine months ended September 30, 2019 : (in millions) Foreign currency Net investment hedging activities Pension and post- Marketable security activities Cash flow hedging Total Balance as of December 31, 2018 $ (830 ) $ (65 ) $ (1,722 ) $ (10 ) $ 147 $ (2,480 ) Other comprehensive income (loss) before reclassifications (288 ) 199 12 12 77 12 Net losses (gains) reclassified from accumulated other comprehensive loss — (15 ) 66 (2 ) (109 ) (60 ) Net current-period other comprehensive income (loss) (288 ) 184 78 10 (32 ) (48 ) Balance as of September 30, 2019 $ (1,118 ) $ 119 $ (1,644 ) $ — $ 115 $ (2,528 ) The following table summarizes the changes in each component of accumulated other comprehensive loss , net of tax, for the nine months ended September 30, 2020 : (in millions) Foreign currency Net investment hedging activities Pension and post-employment Cash flow hedging Total Balance as of December 31, 2019 $ (928 ) $ 9 $ (2,965 ) $ 288 $ (3,596 ) Other comprehensive income (loss) before reclassifications 726 (443 ) (14 ) (49 ) 220 Net losses (gains) reclassified from accumulated other comprehensive loss — (12 ) 148 (19 ) 117 Net current-period other comprehensive income (loss) 726 (455 ) 134 (68 ) 337 Balance as of September 30, 2020 $ (202 ) $ (446 ) $ (2,831 ) $ 220 $ (3,259 )
Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss	The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss : Three months ended Nine months ended (in millions) (brackets denote gains) 2020 2019 2020 2019 Net investment hedging activities Gains on derivative amount excluded from effectiveness testing (a) $ (3 ) $ (10 ) $ (16 ) $ (19 ) Tax expense 1 2 4 4 Total reclassifications, net of tax $ (2 ) $ (8 ) $ (12 ) $ (15 ) Pension and post-employment benefits Amortization of actuarial losses and other (b) $ 63 $ 28 $ 188 $ 83 Tax benefit (13 ) (5 ) (40 ) (17 ) Total reclassifications, net of tax $ 50 $ 23 $ 148 $ 66 Cash flow hedging activities Gains on foreign currency forward exchange contracts (c) $ (15 ) $ (42 ) $ (15 ) $ (119 ) Gains on treasury rate lock agreements (a) (6 ) — (18 ) — Losses on interest rate swap contracts (a) 8 — 10 — Tax expense 3 3 4 10 Total reclassifications, net of tax $ (10 ) $ (39 ) $ (19 ) $ (109 ) (a) Amounts are included in interest expense, net (see Note 8 ). (b) Amounts are included in the computation of net periodic benefit cost (see Note 9 ). (c) Amounts are included in cost of products sold (see Note 8 ).

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Schedule of worldwide net revenues	The following table details AbbVie’s worldwide net revenues: Three months ended Nine months ended (in millions) 2020 2019 2020 2019 Immunology Humira United States $ 4,189 $ 3,887 $ 11,819 $ 10,895 International 951 1,049 2,861 3,357 Total $ 5,140 $ 4,936 $ 14,680 $ 14,252 Skyrizi United States $ 379 $ 76 $ 934 $ 118 International 56 15 131 21 Total $ 435 $ 91 $ 1,065 $ 139 Rinvoq United States $ 191 $ 14 $ 409 $ 14 International 24 — 41 — Total $ 215 $ 14 $ 450 $ 14 Hematologic Oncology Imbruvica United States $ 1,119 $ 1,042 $ 3,140 $ 2,757 Collaboration revenues 251 215 750 621 Total $ 1,370 $ 1,257 $ 3,890 $ 3,378 Venclexta United States $ 204 $ 142 $ 596 $ 364 International 148 79 376 177 Total $ 352 $ 221 $ 972 $ 541 Aesthetics Botox Cosmetic (a) United States $ 237 $ — $ 384 $ — International 156 — 235 — Total $ 393 $ — $ 619 $ — Juvederm Collection (a) United States $ 115 $ — $ 171 $ — International 159 — 216 — Total $ 274 $ — $ 387 $ — Other Aesthetics (a) United States $ 265 $ — $ 392 $ — International 35 — 50 — Total $ 300 $ — $ 442 $ — Neuroscience Botox Therapeutic (a) United States $ 429 $ — $ 683 $ — International 94 — 137 — Total $ 523 $ — $ 820 $ — Vraylar (a) United States $ 358 $ — $ 550 $ — Duodopa United States $ 25 $ 26 $ 75 $ 72 International 98 91 290 271 Total $ 123 $ 117 $ 365 $ 343 Ubrelvy (a) United States $ 38 $ — $ 60 $ — Other Neuroscience (a) United States $ 203 $ — $ 306 $ — International 4 — 6 — Three months ended Nine months ended (in millions) 2020 2019 2020 2019 Total $ 207 $ — $ 312 $ — Eye Care Lumigan/Ganfort (a) United States $ 62 $ — $ 97 $ — International 87 — 128 — Total $ 149 $ — $ 225 $ — Alphagan/Combigan (a) United States $ 84 $ — $ 131 $ — International 39 — 61 — Total $ 123 $ — $ 192 $ — Restasis (a) United States $ 284 $ — $ 422 $ — International 15 — 21 — Total $ 299 $ — $ 443 $ — Other Eye Care (a) United States $ 119 $ — $ 173 $ — International 150 — 224 — Total $ 269 $ — $ 397 $ — Women's Health Lo Loestrin (a) United States $ 129 $ — $ 207 $ — International 5 — 7 — Total $ 134 $ — $ 214 $ — Orilissa/Oriahnn United States $ 24 $ 27 $ 84 $ 58 International 1 — 3 1 Total $ 25 $ 27 $ 87 $ 59 Other Women's Health (a) United States $ 74 $ — $ 108 $ — International 6 — 8 — Total $ 80 $ — $ 116 $ — Other Key Products Mavyret United States $ 185 $ 368 $ 565 $ 1,167 International 229 327 784 1,098 Total $ 414 $ 695 $ 1,349 $ 2,265 Creon United States $ 282 $ 265 $ 810 $ 749 Lupron United States $ 99 $ 187 $ 461 $ 546 International 34 43 110 122 Total $ 133 $ 230 $ 571 $ 668 Linzess/Constella (a) United States $ 240 $ — $ 370 $ — International 8 — 11 — Total $ 248 $ — $ 381 $ — Synthroid United States $ 189 $ 197 $ 577 $ 582 All other $ 829 $ 429 $ 1,972 $ 1,572 Total net revenues $ 12,902 $ 8,479 $ 31,946 $ 24,562 (a) Net revenues for the nine months ended September 30, 2020 include product revenues for Allergan products only from May 8, 2020, which was the acquisition closing date, through September 30, 2020 .

Supplemental Financial Inform_3

Supplemental Financial Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Interest Expense, Net
Interest expense	$ 630	$ 480	$ 1,825	$ 1,225
Interest income	(10)	(60)	(163)	(171)
Interest expense, net	620	420	1,662	1,054
Inventories
Finished goods	1,444		1,444		$ 485
Work-in-process	1,295		1,295		942
Raw materials	735		735		386
Inventories	3,474		3,474		1,813
Property and Equipment
Property and equipment, gross	10,391		10,391		8,188
Accumulated depreciation	(5,405)		(5,405)		(5,226)
Property and equipment, net	4,986		4,986		$ 2,962
Depreciation expense	$ 175	$ 114	$ 439	$ 346

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Basic EPS
Net earnings attributable to AbbVie Inc.	$ 2,308	$ 1,884	$ 4,580	$ 5,081
Earnings allocated to participating securities	17	10	44	27
Earnings available to common shareholders	$ 2,291	$ 1,874	$ 4,536	$ 5,054
Weighted-average basic shares outstanding (in shares)	1,769	1,481	1,633	1,480
Basic earnings per share (in dollars per share)	$ 1.30	$ 1.27	$ 2.78	$ 3.41
Diluted EPS
Net earnings attributable to AbbVie Inc.	$ 2,308	$ 1,884	$ 4,580	$ 5,081
Earnings allocated to participating securities	17	10	44	27
Earnings available to common shareholders	$ 2,291	$ 1,874	$ 4,536	$ 5,054
Weighted-average basic shares outstanding (in shares)	1,769	1,481	1,633	1,480
Effect of dilutive securities (in shares)	5	2	4	3
Weighted-average diluted shares outstanding (in shares)	1,774	1,483	1,637	1,483
Diluted earnings per share (in dollars per share)	$ 1.29	$ 1.26	$ 2.77	$ 3.41

Licensing, Acquisitions, and _3

Licensing, Acquisitions, and Other Arrangements - Acquisition of Allergan (Details) - USD ($) $ / shares in Units, $ in Millions		May 08, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Business Acquisition
Closing price of AbbVie common stock (in dollars per share)		$ 83.96
Amortization of intangible assets			$ 2,100	$ 389		$ 3,967	$ 1,162
Fair Value of Assets Acquired and Liabilities Assumed
Goodwill			42,801		$ 42,801	42,801		$ 15,604
Allergan plc
Business Acquisition
Cash per share received by Allergan shareholders (in dollars per share)		$ 120.30
Amount of AbbVie stock per share received by Allergan shareholders (in shares)		0.8660
Allergan ordinary shares outstanding at closing (in shares)		330,000,000
Shares of AbbVie's common stock issued to Allergan shareholders (in shares)		286,000,000
Stock options issued to Allergan's equity award holders (in shares)		11,200,000
RSUs issued to Allergan's equity award holders (in shares)		8,200,000
Fair value step-up adjustment to inventories		$ 1,200
Fair value step-up adjustment to inventories amortization period					1 year
Weighted average useful life of acquired intangible assets					9 years
Fair value of purchase price adjustment to long-term debt		1,300
Net revenues attributable to Allergan from acquisition date					$ 5,900
Operating losses attributable to Allergan from acquisition date					1,500
Amortization of intangible assets					2,600
Inventory fair value step-up amortization					$ 964
Consideration Transferred
Cash consideration paid to Allergan shareholders	[1]	39,675
Fair value of AbbVie common stock issued to Allergan shareholders	[2]	23,979
Fair value of AbbVie equity stock issued to Allergan equity award holders	[3]	430
Total consideration		64,084
Fair Value of Assets Acquired and Liabilities Assumed
Cash and equivalents		1,537
Short-term investments		1,421
Accounts receivable		2,423
Inventories		2,340
Prepaid expenses and other current assets		1,984
Investments		137
Property and equipment		1,912
Intangible assets - Developed product rights		58,280
Intangible assets - In-process research and development		1,040
Other noncurrent assets		1,452
Short-term borrowings		(60)
Current portion of long-term debt and finance lease obligations		(1,899)
Accounts payable and accrued liabilities		(5,813)
Long-term debt and finance lease obligations		(18,937)
Deferred income taxes		(4,068)
Other long-term liabilities		(4,728)
Total identifiable net assets		37,021
Goodwill		27,063
Total assets acquired and liabilities assumed		$ 64,084
Pro Forma Information
Net revenues			12,902	12,428		36,663	36,085
Net earnings (loss)			2,829	977		6,142	(2,615)
Allergan plc | Selling, general and administrative
Business Acquisition
Acquisition-related expenses			$ 0	$ 26		$ 781	$ 50
[1]	(a) Represents cash consideration transferred of $120.30 per outstanding Allergan ordinary share based on 330 million Allergan ordinary shares outstanding at closing.
[2]	(b) Represents the acquisition date fair value of 286 million shares of AbbVie common stock issued to Allergan shareholders based on the exchange ratio of 0.8660 AbbVie shares for each outstanding Allergan ordinary share at the May 8, 2020 closing price of $83.96 per share.
[3]	(c) Represents the pre-acquisition service portion of the fair value of 11 million AbbVie stock options and 8 million RSUs issued to Allergan equity award holders.

Licensing, Acquisitions, and _4

Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended			9 Months Ended
	Oct. 31, 2020	Dec. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Collaborative and license agreements
Cash outflows related to acquisitions and investments					$ 1,072	$ 476
Acquired in-process research and development			$ 45	$ 0	898	$ 246
Collaborative arrangement | Genmab A/S
Collaborative and license agreements
Potential payments under agreement certain milestones			$ 3,200		3,200
In-process research and development | Collaborative arrangement | Genmab A/S
Collaborative and license agreements
Acquired in-process research and development					$ 750
Forecast | Collaborative arrangement | I-Mab Biopharma
Collaborative and license agreements
Potential payments under agreement certain milestones		$ 1,700
Forecast | In-process research and development | Collaborative arrangement | I-Mab Biopharma
Collaborative and license agreements
Acquired in-process research and development		200
Milestone payment		20
Upfront payment		$ 180
Subsequent event | Luminera
Collaborative and license agreements
Upfront payment to Luminera shareholders	$ 121
Contingent consideration	$ 90

Collaborations (Details)

Collaborations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Collaborative and license agreements
AbbVie's receivable from Janssen	$ 8,416		$ 8,416		$ 5,428
AbbVie's payable to Janssen	19,404		19,404		11,832
Janssen Biotech Inc. | Collaborative arrangement
Collaborative and license agreements
Milestone payments	200		$ 200
Share of collaboration development costs responsible by Janssen (as a percent)			60.00%
Share of collaboration development costs responsible by the entity (as a percent)			40.00%
Global - AbbVie's share of other costs (included in respective line items)	74	$ 81	$ 211	$ 230
AbbVie's receivable from Janssen	276		276		235
AbbVie's payable to Janssen	468		468		$ 455
Janssen Biotech Inc. | Collaborative arrangement | United States
Collaborative and license agreements
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)	524	489	1,467	1,297
Janssen Biotech Inc. | Collaborative arrangement | International
Collaborative and license agreements
International - AbbVie's share of profits (included in net revenues)	251	215	750	621
Genentech, Inc. | Collaborative arrangement
Collaborative and license agreements
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)	139	89	390	220
AbbVie's share of development costs (included in R&D)	27	32	88	94
Genentech, Inc. | Collaborative arrangement | United States
Collaborative and license agreements
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A)	$ 9	$ 9	$ 34	$ 27

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details)	9 Months Ended
	Sep. 30, 2020USD ($)
Changes in the carrying amount of goodwill
Balance at the beginning of the period	$ 15,604,000,000
Additions	27,063,000,000	[1]
Foreign currency translation adjustments	134,000,000
Balance at the end of the period	42,801,000,000
Accumulated goodwill impairment losses
Accumulated goodwill impairment losses	$ 0
[1]	(a) Goodwill additions related to the acquisition of Allergan in the second quarter of 2020 (see Note 4 ).

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Intangible Assets, Net (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Finite-Lived Intangible Assets
Gross carrying amount	$ 86,279,000,000		$ 86,279,000,000		$ 27,345,000,000
Accumulated amortization	(12,676,000,000)		(12,676,000,000)		(8,696,000,000)
Net carrying amount	73,603,000,000		73,603,000,000		18,649,000,000
Indefinite-lived Intangible Assets (Excluding Goodwill)	1,040,000,000		1,040,000,000		0
Intangible Assets, Gross (Excluding Goodwill)	87,319,000,000		87,319,000,000		27,345,000,000
Intangible assets, net	74,643,000,000		74,643,000,000		18,649,000,000
Amortization expense	2,100,000,000	$ 389,000,000	3,967,000,000	$ 1,162,000,000
Definite-lived intangible assets impairment charges	0	0	0	0
Indefinite-lived intangible asset impairment charges	0	$ 1,000,000,000	0	$ 1,000,000,000
Developed product rights
Finite-Lived Intangible Assets
Gross carrying amount	78,451,000,000		78,451,000,000		19,547,000,000
Accumulated amortization	(9,917,000,000)		(9,917,000,000)		(6,405,000,000)
Net carrying amount	68,534,000,000		68,534,000,000		13,142,000,000
License agreements
Finite-Lived Intangible Assets
Gross carrying amount	7,828,000,000		7,828,000,000		7,798,000,000
Accumulated amortization	(2,759,000,000)		(2,759,000,000)		(2,291,000,000)
Net carrying amount	$ 5,069,000,000		$ 5,069,000,000		$ 5,507,000,000

Integration and Restructuring_3

Integration and Restructuring Plans (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Allergan integration plan
Restructuring charges
Expected annual cost synergies			$ 2,000
Integration related costs	$ 2,000		$ 2,000
Allergan integration plan | Research and development
Restructuring charges
Expected annual cost synergies (as a percent)			50.00%
Allergan integration plan | Selling, general and administrative
Restructuring charges
Expected annual cost synergies (as a percent)			40.00%
Allergan integration plan | Cost of products sold
Restructuring charges
Expected annual cost synergies (as a percent)			10.00%
Allergan integration plan | Severance and employee benefits
Restructuring charges
Charges associated with integration or restructuring plans	79		$ 562
Restructuring reserve rollforward
Restructuring charges			467
Payments and other adjustments			(178)
Accrued balance end of the period	289		289
Allergan integration plan | Severance and employee benefits | Research and development
Restructuring charges
Charges associated with integration or restructuring plans	40		172
Allergan integration plan | Severance and employee benefits | Selling, general and administrative
Restructuring charges
Charges associated with integration or restructuring plans	29		347
Allergan integration plan | Severance and employee benefits | Cost of products sold
Restructuring charges
Charges associated with integration or restructuring plans	10		43
Allergan integration plan | Other integration
Restructuring charges
Charges associated with integration or restructuring plans	160		303
Restructuring reserve rollforward
Restructuring charges			303
Payments and other adjustments			(270)
Accrued balance end of the period	33		33
Allergan integration plan | Other integration | Research and development
Restructuring charges
Charges associated with integration or restructuring plans	91		135
Allergan integration plan | Other integration | Selling, general and administrative
Restructuring charges
Charges associated with integration or restructuring plans	57		155
Allergan integration plan | Other integration | Cost of products sold
Restructuring charges
Charges associated with integration or restructuring plans	12		13
Other restructuring
Restructuring charges
Charges associated with integration or restructuring plans	11	$ 22	42	$ 208
Restructuring reserve rollforward
Accrued balance beginning of the period			140
Restructuring charges			40
Payments and other adjustments			(87)
Accrued balance end of the period	$ 93		$ 93

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measures - Financial Instruments (Details) £ in Millions, SFr in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020GBP (£)	Sep. 30, 2020EUR (€)	Sep. 30, 2020CHF (SFr)	Dec. 31, 2019USD ($)	Dec. 31, 2019GBP (£)	Dec. 31, 2019EUR (€)	Dec. 31, 2019CHF (SFr)
Derivative instruments, notional amount and fair value
Amount excluded from the assessment of effectiveness for cash flow hedges	$ 0	$ 0	$ 0	$ 0
Amount excluded from the assessment of effectiveness for fair value hedges	0	0	0	0
Fair value - Derivatives in asset position	220,000,000		220,000,000					$ 53,000,000
Fair value - Derivatives in liability position	110,000,000		110,000,000					132,000,000
Designated as hedging instrument | Net investment hedges | Senior notes
Derivative instruments, notional amount and fair value
Principal amount of unsecured senior notes | €						€ 7,300,000,000				€ 3,600,000,000
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	1,600,000,000		$ 1,600,000,000					957,000,000
Duration of forward exchange contracts			18 months
Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold			6 months
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	0		$ 0					3,000,000
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	32,000,000		32,000,000					14,000,000
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments					£ 204	€ 971,000,000	SFr 62		£ 204	€ 971,000,000	SFr 62
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	14,000,000		14,000,000					0
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	3,000,000		3,000,000					24,000,000
Designated as hedging instrument | Treasury rate lock agreements | Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments		$ 10,000,000,000		$ 10,000,000,000
Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	2,300,000,000		2,300,000,000					2,300,000,000
Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	0		0					0
Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	7,000,000		7,000,000					0
Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges | Other assets
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	0		0					3,000,000
Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges | Other long-term liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	33,000,000		33,000,000					0
Designated as hedging instrument | Interest rate swap contracts | Fair value hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	4,800,000,000		4,800,000,000					10,800,000,000
Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	14,000,000		14,000,000					0
Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	0		0					2,000,000
Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Other assets
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	157,000,000		157,000,000					28,000,000
Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Other long-term liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	0		0					74,000,000
Not designated as hedging instrument | Foreign currency forward exchange contracts
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	8,300,000,000		8,300,000,000					7,100,000,000
Not designated as hedging instrument | Foreign currency forward exchange contracts | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	35,000,000		35,000,000					19,000,000
Not designated as hedging instrument | Foreign currency forward exchange contracts | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	$ 35,000,000		$ 35,000,000					$ 18,000,000

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Cost of products sold
Gain (loss) on derivatives
Pre-tax gains (losses) to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months	$ (22)		$ (22)
Interest expense, net
Gain (loss) on derivatives
Pre-tax gains (losses) to be transferred into interest expense, net for interest rate swap cash flow hedges during the next 12 months	(27)		(27)
Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months	24		24
Interest expense, net | Fair value hedges
Gain (loss) on derivatives
Debt designated as hedged item in fair value hedges gain (loss) recognized in the consolidated statements of earnings	(1)	$ (78)	(398)	$ (443)
Designated as hedging instrument | Senior notes
Gain (loss) on derivatives
Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income	(340)	152	(532)	187
Foreign currency forward exchange contracts | Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	(52)	3	(5)	8
Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income	(56)	59	(32)	69
Foreign currency forward exchange contracts | Designated as hedging instrument | Cost of products sold | Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	15	42	15	119
Foreign currency forward exchange contracts | Designated as hedging instrument | Interest expense, net | Net investment hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	3	10	16	19
Foreign currency forward exchange contracts | Not designated as hedges | Net foreign exchange loss
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	31	(55)	36	(95)
Designated as fair value hedges | Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	(1)	0	(53)	0
Designated as fair value hedges | Designated as hedging instrument | Interest expense, net | Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	(8)	0	(10)	0
Designated as fair value hedges | Designated as hedging instrument | Interest expense, net | Fair value hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	1	78	398	443
Treasury rate lock agreements | Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	0	88	0	88
Treasury rate lock agreements | Designated as hedging instrument | Interest expense, net | Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ 6	$ 0	$ 18	$ 0

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measures - Fair Value Measures (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Assets
Foreign currency contracts	$ 220	$ 53
Liabilities
Foreign currency contracts	110	132
Quoted prices in active markets for identical assets (Level 1)
Liabilities
Total liabilities	92,868	70,384
Fair Value, Recurring
Assets
Cash and equivalents	7,890	39,924
Debt securities	53	3
Equity securities	146	24
Interest rate swap contracts	171	31
Total assets	8,320	40,004
Liabilities
Interest rate swap contracts	40	76
Contingent consideration	8,327	7,340
Total liabilities	8,437	7,472
Fair Value, Recurring | Foreign currency contracts
Assets
Foreign currency contracts	49	22
Liabilities
Foreign currency contracts	70	56
Fair Value, Recurring | Quoted prices in active markets for identical assets (Level 1)
Assets
Cash and equivalents	2,836	1,542
Debt securities	0	0
Equity securities	138	24
Interest rate swap contracts	0	0
Total assets	2,974	1,566
Liabilities
Interest rate swap contracts	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Recurring | Quoted prices in active markets for identical assets (Level 1) | Foreign currency contracts
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	0	0
Fair Value, Recurring | Significant other observable inputs (Level 2)
Assets
Cash and equivalents	5,054	38,382
Debt securities	53	3
Equity securities	8	0
Interest rate swap contracts	171	31
Total assets	5,346	38,438
Liabilities
Interest rate swap contracts	40	76
Contingent consideration	0	0
Total liabilities	110	132
Fair Value, Recurring | Significant other observable inputs (Level 2) | Foreign currency contracts
Assets
Foreign currency contracts	49	22
Liabilities
Foreign currency contracts	70	56
Fair Value, Recurring | Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	0	0
Debt securities	0	0
Equity securities	0	0
Interest rate swap contracts	0	0
Total assets	0	0
Liabilities
Interest rate swap contracts	0	0
Contingent consideration	8,327	7,340
Total liabilities	8,327	7,340
Fair Value, Recurring | Significant unobservable inputs (Level 3) | Foreign currency contracts
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	0	$ 0
Money market funds and time deposits | Fair Value, Recurring
Assets
Money market funds and time deposits	11
Money market funds and time deposits | Fair Value, Recurring | Quoted prices in active markets for identical assets (Level 1)
Assets
Money market funds and time deposits	0
Money market funds and time deposits | Fair Value, Recurring | Significant other observable inputs (Level 2)
Assets
Money market funds and time deposits	11
Money market funds and time deposits | Fair Value, Recurring | Significant unobservable inputs (Level 3)
Assets
Money market funds and time deposits	$ 0

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)	Sep. 30, 2020
Probability of payment for early stage indications
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0	[1],[2]
Probability of payment for approved indications
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	1	[1],[2]
Weighted average | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.015	[2]
Weighted average | Probability of payment for unachieved milestones
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.54	[2]
Weighted average | Probability of payment for royalties by indication
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.89	[1],[2]
Weighted average | Projected year of payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	2,027	[2]
Minimum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.002
Minimum | Probability of payment for unachieved milestones
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.16
Minimum | Probability of payment for royalties by indication
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.16	[1]
Minimum | Projected year of payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	2,020
Minimum | Probability of payment for royalties excluding early stage or approved indications
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.16	[1]
Maximum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.026
Maximum | Probability of payment for unachieved milestones
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.57
Maximum | Probability of payment for royalties by indication
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	1	[1]
Maximum | Projected year of payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	2,034
Maximum | Probability of payment for royalties excluding early stage or approved indications
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.56	[1]
[1]	(b) Excludes early stage indications with 0% estimated probability of payment and includes approved indications with 100% probability of payment. Excluding approved indications, the estimated probability of payment ranged from 16% to 56% at September 30, 2020 .
[2]	(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.

Financial Instruments and Fai_7

Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details) - USD ($)		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019
Transfers of assets or liabilities between the fair value measurement levels
Transfers of assets into Level 3 of the fair value hierarchy		$ 0
Transfers of assets out of Level 3 of the fair value hierarchy		0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]
Transfers of liabilities into Level 3 of the fair value hierarchy		0
Transfers of liabilities out of Level 3 of the fair value hierarchy		0
Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)
Beginning balance		7,340,000,000	$ 4,483,000,000
Additions	[1]	121,000,000	0
Change in fair value recognized in net earnings		(1,078,000,000)	(2,653,000,000)
Payments		(212,000,000)	(179,000,000)
Ending balance		$ 8,327,000,000	$ 6,957,000,000
[1]	(a) Represents contingent consideration liabilities assumed in the Allergan acquisition.

Financial Instruments and Fai_8

Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Liabilities
Carrying amount of investments in equity securities that do not have readily determinable fair values	$ 96	$ 66
Quoted prices in active markets for identical assets (Level 1)
Liabilities
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	4,279	3,753
Long-term debt and finance lease obligations, excluding fair value hedges	88,589	66,631
Total liabilities	92,868	70,384
Book value
Liabilities
Short-term Debt, Fair Value	54
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	4,709	3,755
Long-term debt and finance lease obligations, excluding fair value hedges	81,972	63,021
Total liabilities	86,735	66,776
Approximate fair value
Liabilities
Short-term Debt, Fair Value	54
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	4,732	3,760
Long-term debt and finance lease obligations, excluding fair value hedges	90,201	66,651
Total liabilities	94,987	70,411
Approximate fair value | Quoted prices in active markets for identical assets (Level 1)
Liabilities
Short-term Debt, Fair Value	0
Approximate fair value | Significant other observable inputs (Level 2)
Liabilities
Short-term Debt, Fair Value	54
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	453	7
Long-term debt and finance lease obligations, excluding fair value hedges	1,612	20
Total liabilities	2,119	27
Approximate fair value | Significant unobservable inputs (Level 3)
Liabilities
Short-term Debt, Fair Value	0
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	0	0
Long-term debt and finance lease obligations, excluding fair value hedges	0	0
Total liabilities	$ 0	$ 0

Financial Instruments and Fai_9

Financial Instruments and Fair Value Measures - Concentrations of Risk (Details) - wholesaler	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Accounts receivable, net
Concentration of Risk
Number of principal customers	3
Accounts receivable, net | Geographic Risk
Concentration of Risk
Concentrations risk (as a percent)	67.00%		68.00%
Total revenues | HUMIRA
Concentration of Risk
Concentrations risk (as a percent)	46.00%	58.00%

Financial Instruments and Fa_10

Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details) € in Millions	1 Months Ended		9 Months Ended
	Sep. 30, 2020USD ($)	May 31, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020EUR (€)	May 31, 2020EUR (€)	Sep. 30, 2019EUR (€)
Debt Instrument [Line Items]
Repayment of long-term debt			$ 4,414,000,000	$ 5,000,000
Total acquired debt outstanding
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 20,426,000,000		20,426,000,000
Unamortized purchase price adjustments of Allergan debt	1,256,000,000		1,256,000,000
Term loan facilities | May 2020 floating rate term loans
Debt Instrument [Line Items]
Principal amount of debt		$ 3,000,000,000
Term loan facilities | July 2019 term loan agreement
Debt Instrument [Line Items]
Maximum borrowing capacity of term loan credit agreement		$ 6,000,000,000
Term loan facilities | Floating rate term loan tranche due May 2023
Debt Instrument [Line Items]
Long-term debt obligations, gross	1,000,000,000		1,000,000,000
Term loan credit agreement term		3 years
Term loan facilities | Floating rate term loan tranche due May 2023
Debt Instrument [Line Items]
Long-term debt obligations, gross	2,000,000,000		$ 2,000,000,000
Term loan credit agreement term		5 years
Senior notes | Allergan notes exchanged
Debt Instrument [Line Items]
Long-term debt obligations, gross		$ 14,000,000,000
Senior notes | Allergan Euro notes exchanged
Debt Instrument [Line Items]
Long-term debt obligations, gross | €						€ 3,100
Senior notes | Allergan notes assumed
Debt Instrument [Line Items]
Long-term debt obligations, gross		1,500,000,000
Senior notes | Allergan Euro notes assumed
Debt Instrument [Line Items]
Long-term debt obligations, gross | €						€ 635
Senior notes | 3.375% Senior Notes due 2020
Debt Instrument [Line Items]
Repayment of long-term debt	$ 650,000,000
Stated interest rate (as a percent)	3.375%		3.375%		3.375%
Senior notes | 4.875% Senior Notes due 2021
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 450,000,000		$ 450,000,000
Stated interest rate (as a percent)	4.875%		4.875%		4.875%
Senior notes | 5.000% Senior Notes due 2021
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 1,200,000,000		$ 1,200,000,000
Stated interest rate (as a percent)	5.00%		5.00%		5.00%
Senior notes | 3.450% Senior Notes due 2022
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 2,878,000,000		$ 2,878,000,000
Stated interest rate (as a percent)	3.45%		3.45%		3.45%
Senior notes | 3.250% Senior Notes due 2022
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 1,700,000,000		$ 1,700,000,000
Stated interest rate (as a percent)	3.25%		3.25%		3.25%
Senior notes | 2.800% Senior Notes due 2023
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 350,000,000		$ 350,000,000
Stated interest rate (as a percent)	2.80%		2.80%		2.80%
Senior notes | 3.850% Senior Notes due 2024
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 1,032,000,000		$ 1,032,000,000
Stated interest rate (as a percent)	3.85%		3.85%		3.85%
Senior notes | 3.800% Senior Notes due 2025
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 3,021,000,000		$ 3,021,000,000
Stated interest rate (as a percent)	3.80%		3.80%		3.80%
Senior notes | 4.550% Senior Notes due 2035
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 1,789,000,000		$ 1,789,000,000
Stated interest rate (as a percent)	4.55%		4.55%		4.55%
Senior notes | 4.625% Senior Notes due 2042
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 457,000,000		$ 457,000,000
Stated interest rate (as a percent)	4.625%		4.625%		4.625%
Senior notes | 4.850% Senior Notes due 2044
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 1,074,000,000		$ 1,074,000,000
Stated interest rate (as a percent)	4.85%		4.85%		4.85%
Senior notes | 4.750% Senior Notes due 2045
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 881,000,000		$ 881,000,000
Stated interest rate (as a percent)	4.75%		4.75%		4.75%
Senior notes | Floating Rate Notes due 2020 (€700 principal)
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 821,000,000		$ 821,000,000
Aggregate principal amount of debt | €					€ 700
Senior notes | 0.500% Senior Notes due 2021 (€750 principal)
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 879,000,000		$ 879,000,000
Stated interest rate (as a percent)	0.50%		0.50%		0.50%
Aggregate principal amount of debt | €					€ 750
Senior notes | 1.500% Senior Notes due 2023 (€500 principal)
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 586,000,000		$ 586,000,000
Stated interest rate (as a percent)	1.50%		1.50%		1.50%
Aggregate principal amount of debt | €					€ 500
Senior notes | 1.250% Senior Notes due 2024 (€700 principal)
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 821,000,000		$ 821,000,000
Stated interest rate (as a percent)	1.25%		1.25%		1.25%
Aggregate principal amount of debt | €					€ 700
Senior notes | 2.625% Senior Notes due 2028 (€500 principal)
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 586,000,000		$ 586,000,000
Stated interest rate (as a percent)	2.625%		2.625%		2.625%
Aggregate principal amount of debt | €					€ 500
Senior notes | 2.125% Senior Notes due 2029 (€550 principal)
Debt Instrument [Line Items]
Long-term debt obligations, gross	$ 645,000,000		$ 645,000,000
Stated interest rate (as a percent)	2.125%		2.125%		2.125%
Aggregate principal amount of debt | €					€ 550
Senior notes | 2.5% Senior Notes due May 2020
Debt Instrument [Line Items]
Repayment of long-term debt		$ 3,800,000,000
Stated interest rate (as a percent)		2.50%				2.50%
Senior notes | September 2019 Senior Euro Notes
Debt Instrument [Line Items]
Aggregate principal amount of debt | €							€ 1,400
Senior notes | Senior Euro Notes Due in 2027 at 0.750 Percent
Debt Instrument [Line Items]
Stated interest rate (as a percent)		0.75%				0.75%
Aggregate principal amount of debt | €							750
Senior notes | Sec 1.250 Senior Notes due 2031
Debt Instrument [Line Items]
Aggregate principal amount of debt | €							€ 650
Senior notes | Senior Euro Notes Due in 2031 at 1.250 Percent
Debt Instrument [Line Items]
Stated interest rate (as a percent)		1.25%				1.25%

Financial Instruments and Fa_11

Financial Instruments and Fair Value Measures - Short-Term Borrowings (Details) - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Short-Term Borrowings
Short-term borrowings		$ 54		$ 0
Repayments of other short-term borrowings		0	$ 3,000
Commercial paper
Short-Term Borrowings
Short-term borrowings		$ 0		$ 0
Weighted-average interest rate on commercial paper (as a percent)		1.80%	2.50%
Term loan facilities | May 2018 term loan credit agreement
Short-Term Borrowings
Repayments of other short-term borrowings	$ 3,000
Term loan credit agreement term	364 days

Post-Employment Benefits (Detai

Post-Employment Benefits (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	May 08, 2020
Defined benefit plans
Defined benefit and other post-employment plans
Service cost	$ 93	$ 67	$ 277	$ 202
Interest cost	68	64	196	194
Expected return on plan assets	(148)	(118)	(426)	(356)
Amortization of actuarial losses and prior service cost	57	27	171	82
Net periodic benefit cost	70	40	218	122
Other post-employment plans
Defined benefit and other post-employment plans
Service cost	10	6	31	19
Interest cost	8	6	25	21
Expected return on plan assets	0	0	0	0
Amortization of actuarial losses and prior service cost	7	1	17	1
Net periodic benefit cost	$ 25	$ 13	$ 73	$ 41
Allergan plc | Defined benefit plans
Defined benefit and other post-employment plans
Post-employment benefit obligations liability assumed					$ 156

Equity - Stock-Based Compensati

Equity - Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	$ 162	$ 75	$ 617	$ 351
Tax benefit	32	15	109	64
After-tax compensation expense	130	60	508	287
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	11	4	37	24
Research and development
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	54	31	200	136
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	$ 97	$ 40	$ 380	$ 191

Equity - Stock Options (Details

Equity - Stock Options (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2020	May 08, 2020
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award
Stock options granted (in shares)	2
Weighted-average grant-date fair value of the stock options granted (in dollars per share)	$ 12.14
Unrecognized compensation cost	$ 16
Period for recognition of unrecognized compensation cost	2 years
Allergan plc
Share-based Compensation Arrangement by Share-based Payment Award
Stock options issued to Allergan's equity award holders (in shares)		11.2

Equity - RSUs and Performance S

Equity - RSUs and Performance Shares (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2020	May 08, 2020
RSUs and Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award
Shares granted (in shares)	5.5
Fair market value of awards vested (in dollars per share)	$ 93.50
Unrecognized compensation cost	$ 713
Period for recognition of unrecognized compensation cost	2 years
Allergan plc
Share-based Compensation Arrangement by Share-based Payment Award
RSUs issued to Allergan's equity award holders (in shares)		8.2

Equity - Cash Dividends (Detail

Equity - Cash Dividends (Details) - $ / shares	Oct. 30, 2020	Sep. 11, 2020	Jun. 17, 2020	Feb. 20, 2020	Nov. 01, 2019	Sep. 06, 2019	Jun. 20, 2019	Feb. 21, 2019
Dividends Payable
Cash dividends declared per common share (in dollars per share)		$ 1.18	$ 1.18	$ 1.18	$ 1.18	$ 1.07	$ 1.07	$ 1.07
Subsequent event
Dividends Payable
Cash dividends declared per common share (in dollars per share)	$ 1.30

Equity - Stock Repurchase Progr

Equity - Stock Repurchase Program (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Equity, Class of Treasury Stock
Payment for shares repurchased	$ 20	$ 3	$ 682	$ 425
Remaining share repurchase authorization amount	$ 3,500		$ 3,500
December 2018 Stock Repurchase Authorization
Equity, Class of Treasury Stock
Shares repurchased (in shares)			6	4
Payment for shares repurchased			$ 500	$ 300

Equity - Accumulated Other Comp

Equity - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 14,732	$ (8,566)	$ (8,172)	$ (8,446)
Other comprehensive income (loss)	176	(37)	337	(48)
Ending balance	15,289	(8,226)	15,289	(8,226)
Foreign currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			(928)	(830)
Other comprehensive income (loss) before reclassifications			726	(288)
Net losses (gains) reclassified from accumulated other comprehensive loss			0	0
Other comprehensive income (loss)			726	(288)
Ending balance	(202)	(1,118)	(202)	(1,118)
Net investment hedging activities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			9	(65)
Other comprehensive income (loss) before reclassifications			(443)	199
Net losses (gains) reclassified from accumulated other comprehensive loss			(12)	(15)
Other comprehensive income (loss)			(455)	184
Ending balance	(446)	119	(446)	119
Pension and post-employment benefits
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			(2,965)	(1,722)
Other comprehensive income (loss) before reclassifications			(14)	12
Net losses (gains) reclassified from accumulated other comprehensive loss	50	23	148	66
Other comprehensive income (loss)			134	78
Ending balance	(2,831)	(1,644)	(2,831)	(1,644)
Marketable securities activities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance				(10)
Other comprehensive income (loss) before reclassifications				12
Net losses (gains) reclassified from accumulated other comprehensive loss				(2)
Other comprehensive income (loss)				10
Ending balance		0		0
Cash flow hedging activities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			288	147
Other comprehensive income (loss) before reclassifications			(49)	77
Net losses (gains) reclassified from accumulated other comprehensive loss			(19)	(109)
Other comprehensive income (loss)			(68)	(32)
Ending balance	220	115	220	115
Accumulated other comprehensive income (loss)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			(3,596)	(2,480)
Other comprehensive income (loss) before reclassifications			220	12
Net losses (gains) reclassified from accumulated other comprehensive loss			117	(60)
Other comprehensive income (loss)			337	(48)
Ending balance	$ (3,259)	$ (2,528)	(3,259)	(2,528)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Other comprehensive income (loss) before reclassifications			$ 726	$ 288

Equity - Amounts Reclassified O

Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Significant amounts reclassified out of each component of AOCI
Gains on derivative amount excluded from effectiveness testing		$ (620)	$ (420)	$ (1,662)	$ (1,054)
Tax expense (benefit)		187	117	321	271
Total reclassifications, net of tax		(2,308)	(1,884)	(4,580)	(5,081)
Losses (gains) on foreign currency forward exchange contracts		5,050	1,920	10,703	5,433
Pension and post-employment benefits
Significant amounts reclassified out of each component of AOCI
Amortization of actuarial losses and other	[1]	63	28	188	83
Tax benefit		(13)	(5)	(40)	(17)
Total reclassifications, net of tax		50	23	148	66
Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Total reclassifications, net of tax				(19)	(109)
Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Tax expense (benefit)		3	3	4	10
Total reclassifications, net of tax		(10)	(39)	(19)	(109)
Reclassification out of accumulated other comprehensive loss | Net investment hedging activity | Net investment hedging activities
Significant amounts reclassified out of each component of AOCI
Gains on derivative amount excluded from effectiveness testing	[2]	3	10	16	19
Tax expense (benefit)		1	2	4	4
Total reclassifications, net of tax		(2)	(8)	(12)	(15)
Foreign currency forward exchange contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Losses (gains) on foreign currency forward exchange contracts	[3]	(15)	(42)	(15)	(119)
Treasury rate lock agreements | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Gains on derivative amount excluded from effectiveness testing	[2]	(6)	0	(18)	0
Interest rate swap contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Gains on derivative amount excluded from effectiveness testing	[2]	$ 8	$ 0	$ 10	$ 0
[1]	(b) Amounts are included in the computation of net periodic benefit cost (see Note 9 ).
[2]	(a) Amounts are included in interest expense, net (see Note 8
[3]	(c) Amounts are included in cost of products sold (see Note 8 ).

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Effective tax rate	7.00%	6.00%	7.00%	5.00%
U.S. statutory tax rate			21.00%	21.00%
Potential change in unrecognized tax benefits	$ 138		$ 138

Legal Proceedings and Conting_2

Legal Proceedings and Contingencies (Details) $ in Millions	1 Months Ended				9 Months Ended
	Sep. 30, 2020USD ($)claimcompany	Jun. 30, 2018USD ($)	Jun. 30, 2016investment_fund	Sep. 30, 2014company	Sep. 30, 2020USD ($)claim	Sep. 30, 2020USD ($)claimdirect_purchaser	Sep. 30, 2020USD ($)claimlawsuit	Sep. 30, 2020USD ($)claimclass_action	Sep. 30, 2020USD ($)claimend_payor_purchaser	Dec. 31, 2019USD ($)
Legal Proceedings and Contingencies
Recorded accrual balance for litigation | $	$ 70				$ 70	$ 70	$ 70	$ 70	$ 70	$ 290
Percentage of claims subject to settlement agreements					95.00%
Depakote litigation in the District Court for the Southern District of Illinois
Legal Proceedings and Contingencies
Number of claims pending	120				120	120	120	120	120
Depakote litigation in federal and state courts
Legal Proceedings and Contingencies
Number of claims pending	4				4	4	4	4	4
Niaspan
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits | lawsuit							4
Number of purported class actions | class_action								2
Number of healthcare benefit providers acting as plaintiff in lawsuit						1			1
AndroGel antitrust litigation
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into | company				2
Number of generic companies named in claim whose court finding was reversed | company	1
AndroGel antitrust litigation | Disgorgement remedy
Legal Proceedings and Contingencies
Damages awarded against company | $		$ 448
Prescription drug abuse litigation
Legal Proceedings and Contingencies
Number of claims pending	3,050				3,050	3,050	3,050	3,050	3,050
Prescription drug abuse litigation in state courts
Legal Proceedings and Contingencies
Number of claims pending	279				279	279	279	279	279
Elliott Associates, L.P.
Legal Proceedings and Contingencies
Number of parties to lawsuit (in investment funds) | investment_fund			5
Generic drug pricing securities litigation in U.S. District Court of New Jersey
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits | lawsuit							1
Number of purported class actions | class_action								3
Testosterone Replacement Therapy Products Liability Litigation
Legal Proceedings and Contingencies
Number of claims pending	175				175	175	175	175	175
Number of claims consolidated for pre-trial purposes	3,500				3,500	3,500	3,500	3,500	3,500
Claims not being settled in master settlement agreement | Testosterone Replacement Therapy Products Liability Litigation
Legal Proceedings and Contingencies
Number of claims pending	5				5	5	5	5	5

Segment Information - Additiona

Segment Information - Additional Information (Details)	9 Months Ended
	Sep. 30, 2020segment
Segment Reporting [Abstract]
Number of operating segments	1

Segment Information - Disaggreg

Segment Information - Disaggregation of Revenue (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue
Total net revenues		$ 12,902	$ 8,479	$ 31,946	$ 24,562
All other
Disaggregation of Revenue
Net revenues		829	429	1,972	1,572
Immunology | Humira
Disaggregation of Revenue
Net revenues		5,140	4,936	14,680	14,252
Immunology | Humira | United States
Disaggregation of Revenue
Net revenues		4,189	3,887	11,819	10,895
Immunology | Humira | International
Disaggregation of Revenue
Net revenues		951	1,049	2,861	3,357
Immunology | Skyrizi
Disaggregation of Revenue
Net revenues		435	91	1,065	139
Immunology | Skyrizi | United States
Disaggregation of Revenue
Net revenues		379	76	934	118
Immunology | Skyrizi | International
Disaggregation of Revenue
Net revenues		56	15	131	21
Immunology | Rinvoq
Disaggregation of Revenue
Net revenues		215	14	450	14
Immunology | Rinvoq | United States
Disaggregation of Revenue
Net revenues		191	14	409	14
Immunology | Rinvoq | International
Disaggregation of Revenue
Net revenues		24	0	41	0
Hematologic Oncology | Imbruvica
Disaggregation of Revenue
Net revenues		1,370	1,257	3,890	3,378
Hematologic Oncology | Imbruvica | United States
Disaggregation of Revenue
Net revenues		1,119	1,042	3,140	2,757
Hematologic Oncology | Imbruvica | International
Disaggregation of Revenue
Collaboration revenues		251	215	750	621
Hematologic Oncology | Venclexta
Disaggregation of Revenue
Net revenues		352	221	972	541
Hematologic Oncology | Venclexta | United States
Disaggregation of Revenue
Net revenues		204	142	596	364
Hematologic Oncology | Venclexta | International
Disaggregation of Revenue
Net revenues		148	79	376	177
Aesthetics | Botox Cosmetic
Disaggregation of Revenue
Net revenues	[1]	393	0	619	0
Aesthetics | Botox Cosmetic | United States
Disaggregation of Revenue
Net revenues	[1]	237	0	384	0
Aesthetics | Botox Cosmetic | International
Disaggregation of Revenue
Net revenues	[1]	156	0	235	0
Aesthetics | Juvederm Collection
Disaggregation of Revenue
Net revenues	[1]	274	0	387	0
Aesthetics | Juvederm Collection | United States
Disaggregation of Revenue
Net revenues	[1]	115	0	171	0
Aesthetics | Juvederm Collection | International
Disaggregation of Revenue
Net revenues	[1]	159	0	216	0
Aesthetics | Other Aesthetics
Disaggregation of Revenue
Net revenues	[1]	300	0	442	0
Aesthetics | Other Aesthetics | United States
Disaggregation of Revenue
Net revenues	[1]	265	0	392	0
Aesthetics | Other Aesthetics | International
Disaggregation of Revenue
Net revenues	[1]	35	0	50	0
Neuroscience | Botox Therapeutic
Disaggregation of Revenue
Net revenues	[1]	523	0	820	0
Neuroscience | Botox Therapeutic | United States
Disaggregation of Revenue
Net revenues	[1]	429	0	683	0
Neuroscience | Botox Therapeutic | International
Disaggregation of Revenue
Net revenues	[1]	94	0	137	0
Neuroscience | Vraylar | United States
Disaggregation of Revenue
Net revenues	[1]	358	0	550	0
Neuroscience | Duodopa
Disaggregation of Revenue
Net revenues		123	117	365	343
Neuroscience | Duodopa | United States
Disaggregation of Revenue
Net revenues		25	26	75	72
Neuroscience | Duodopa | International
Disaggregation of Revenue
Net revenues		98	91	290	271
Neuroscience | Ubrelvy | United States
Disaggregation of Revenue
Net revenues	[1]	38	0	60	0
Neuroscience | Other Neuroscience
Disaggregation of Revenue
Net revenues	[1]	207	0	312	0
Neuroscience | Other Neuroscience | United States
Disaggregation of Revenue
Net revenues	[1]	203	0	306	0
Neuroscience | Other Neuroscience | International
Disaggregation of Revenue
Net revenues	[1]	4	0	6	0
Eye Care | Lumigan/Ganfort
Disaggregation of Revenue
Net revenues	[1]	149	0	225	0
Eye Care | Lumigan/Ganfort | United States
Disaggregation of Revenue
Net revenues	[1]	62	0	97	0
Eye Care | Lumigan/Ganfort | International
Disaggregation of Revenue
Net revenues	[1]	87	0	128	0
Eye Care | Alphagan/Combigan
Disaggregation of Revenue
Net revenues	[1]	123	0	192	0
Eye Care | Alphagan/Combigan | United States
Disaggregation of Revenue
Net revenues	[1]	84	0	131	0
Eye Care | Alphagan/Combigan | International
Disaggregation of Revenue
Net revenues	[1]	39	0	61	0
Eye Care | Restasis
Disaggregation of Revenue
Net revenues	[1]	299	0	443	0
Eye Care | Restasis | United States
Disaggregation of Revenue
Net revenues	[1]	284	0	422	0
Eye Care | Restasis | International
Disaggregation of Revenue
Net revenues	[1]	15	0	21	0
Eye Care | Other Eye Care
Disaggregation of Revenue
Net revenues	[1]	269	0	397	0
Eye Care | Other Eye Care | United States
Disaggregation of Revenue
Net revenues	[1]	119	0	173	0
Eye Care | Other Eye Care | International
Disaggregation of Revenue
Net revenues	[1]	150	0	224	0
Women's Health | Lo Loestrin
Disaggregation of Revenue
Net revenues	[1]	134	0	214	0
Women's Health | Lo Loestrin | United States
Disaggregation of Revenue
Net revenues	[1]	129	0	207	0
Women's Health | Lo Loestrin | International
Disaggregation of Revenue
Net revenues	[1]	5	0	7	0
Women's Health | Orilissa/Oriahnn
Disaggregation of Revenue
Net revenues		25	27	87	59
Women's Health | Orilissa/Oriahnn | United States
Disaggregation of Revenue
Net revenues		24	27	84	58
Women's Health | Orilissa/Oriahnn | International
Disaggregation of Revenue
Net revenues		1	0	3	1
Women's Health | Other Women's Health
Disaggregation of Revenue
Net revenues	[1]	80	0	116	0
Women's Health | Other Women's Health | United States
Disaggregation of Revenue
Net revenues	[1]	74	0	108	0
Women's Health | Other Women's Health | International
Disaggregation of Revenue
Net revenues	[1]	6	0	8	0
Other Key Products | Mavyret
Disaggregation of Revenue
Net revenues		414	695	1,349	2,265
Other Key Products | Mavyret | United States
Disaggregation of Revenue
Net revenues		185	368	565	1,167
Other Key Products | Mavyret | International
Disaggregation of Revenue
Net revenues		229	327	784	1,098
Other Key Products | Creon | United States
Disaggregation of Revenue
Net revenues		282	265	810	749
Other Key Products | Lupron
Disaggregation of Revenue
Net revenues		133	230	571	668
Other Key Products | Lupron | United States
Disaggregation of Revenue
Net revenues		99	187	461	546
Other Key Products | Lupron | International
Disaggregation of Revenue
Net revenues		34	43	110	122
Other Key Products | Linzess/Constella
Disaggregation of Revenue
Net revenues	[1]	248	0	381	0
Other Key Products | Linzess/Constella | United States
Disaggregation of Revenue
Net revenues	[1]	240	0	370	0
Other Key Products | Linzess/Constella | International
Disaggregation of Revenue
Net revenues	[1]	8	0	11	0
Other Key Products | Synthroid | United States
Disaggregation of Revenue
Net revenues		$ 189	$ 197	$ 577	$ 582
[1]	(a) Net revenues for the nine months ended September 30, 2020 include product revenues for Allergan products only from May 8, 2020, which was the acquisition closing date, through September 30, 2020 .